

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 04
April 2009**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2009

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

Cumulative Supplement 4

April 2009

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Availability of the Edition	v
1.5 Report of Counts for the Prescription Drug Product List	vi
1.6 Cumulative Supplement Legend	vii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

**CUMULATIVE SUPPLEMENT 4
April 2009**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 28th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 29th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 30th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@cder.fda.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
DABUR ONCOLOGY PLC (DABUR ONCOLOGY PLC)	FRESENIUS KABI ONCOLOGY PLC (FRESENIUS KABI ONCOL)
TORPHARM INC (TORPHARM)	APOTEX INC (APOTEX)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.fda.gov/cder/ob/default.htm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Annual Edition. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm>

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are provided in eobzip.exe and eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not

previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2008</u>	<u>MAR 2009</u>	<u>JUN 2009</u>	<u>SEPT 2009</u>
DRUG PRODUCTS LISTED	12751	12910		
SINGLE SOURCE	2433	2449		
	(19.1%)	(19.0%)		
MULTISOURCE	10229	10372		
	(80.2%)	(80.3%)		
THERAPEUTICALLY EQUIVALENT	10072	10216		
	(79.0%)	(79.1%)		
NOT THERAPEUTICALLY EQUIVALENT	157	156		
	(1.2%)	(1.2%)		
EXCEPTIONS ¹	89	89		
	(0.7%)	(0.7%)		
NEW MOLECULAR ENTITIES APPROVED	15	5		
NUMBER OF APPLICANTS	719	724		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 28TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

1-1

ACETAMINOPHEN; CODEINE PHOSPHATE

	TABLET; ORAL							
	ACETAMINOPHEN AND CODEINE PHOSPHATE							
	@ SANDOZ	300MG;30MG	N81250	001	Jul 16, 1992	Mar	DISC	
	@	300MG;60MG	N81249	001	Jul 16, 1992	Mar	DISC	
	TYLENOL W/ CODEINE NO. 4							
AA	ORTHO MCNEIL JANSSEN	300MG;60MG	N85055	004		Mar	CMFD	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

	CAPSULE; ORAL							
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
	@ MALLINCKRODT	500MG;5MG	N89006	001	Aug 09, 1985	Feb	CTNA	

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

	TABLET; ORAL							
	PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN							
	@ SANDOZ	650MG;65MG	N89959	001	Jul 18, 1989	Mar	DISC	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

	TABLET; ORAL							
	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN							
	@ SANDOZ	650MG;100MG	N70443	001	Jan 23, 1986	Mar	DISC	

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

	TABLET; ORAL							
	TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN							
>D>	AB	ALPHAPHARM	325MG;37.5MG	N77858	001	Sep 26, 2008	Apr	CAHN
>A>	AB	MYLAN	325MG;37.5MG	N77858	001	Sep 26, 2008	Apr	CAHN

ACETAZOLAMIDE SODIUM

	INJECTABLE; INJECTION							
	ACETAZOLAMIDE SODIUM							
>D>	AP	HOSPIRA	EQ 500MG BASE/VIAL	N40108	001	Oct 30, 1995	Apr	DISC
>A>		@	EQ 500MG BASE/VIAL	N40108	001	Oct 30, 1995	Apr	DISC

ACYCLOVIR SODIUM

	INJECTABLE; INJECTION							
	ACYCLOVIR SODIUM							
>D>	AP	HOSPIRA	EQ 500MG BASE/VIAL	N74758	001	Apr 22, 1997	Apr	DISC
>A>		@	EQ 500MG BASE/VIAL	N74758	001	Apr 22, 1997	Apr	DISC
>D>	AP		EQ 1GM BASE/VIAL	N74758	002	Apr 22, 1997	Apr	DISC
>A>		@	EQ 1GM BASE/VIAL	N74758	002	Apr 22, 1997	Apr	DISC

ADENOSINE

	INJECTABLE; INJECTION							
	ADENOSINE							
>A>	AP	LUITPOLD	3MG/ML	N90010	001	Apr 28, 2009	Apr	NEWA

ALBUTEROL

	AEROSOL, METERED; INHALATION							
	ALBUTEROL							
	@ ARMSTRONG PHARMS	0.09MG/INH	N72273	001	Aug 14, 1996	Jan	DISC	

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

>D>	AN	+	BAUSCH AND LOMB	EQ 0.083% BASE	N75358 001	Mar 29, 2000	Apr	DISC
>A>			@	EQ 0.083% BASE	N75358 001	Mar 29, 2000	Apr	DISC
	AN		HOLOPACK INTL	EQ 0.083% BASE	N77839 001	Dec 16, 2008	Jan	CAHN
>D>	AN		IVAX PHARMS	EQ 0.083% BASE	N75343 001	Nov 09, 1999	Apr	CAHN
>A>	AN		TEVA PARENTERAL	EQ 0.083% BASE	N75343 001	Nov 09, 1999	Apr	CAHN

TABLET; ORAL

ALBUTEROL SULFATE

@ SANDOZ

EQ 2MG BASE

N72151 001 Dec 05, 1989 Mar DISC

@

EQ 4MG BASE

N72152 001 Dec 05, 1989 Mar DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

>D>	AN		IVAX PHARMS INC	EQ 0.083% BASE;0.017%	N76724 001	Dec 31, 2007	Apr	CAHN
>A>	AN		TEVA PARENTERAL	EQ 0.083% BASE;0.017%	N76724 001	Dec 31, 2007	Apr	CAHN

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

>A>	AB		SANDOZ	EQ 5MG BASE	N75871 001	Apr 22, 2009	Apr	NEWA
>A>	AB			EQ 10MG BASE	N75871 002	Apr 22, 2009	Apr	NEWA
>A>	AB			EQ 35MG BASE	N75871 004	Apr 22, 2009	Apr	NEWA
>A>	AB			EQ 40MG BASE	N75871 003	Apr 22, 2009	Apr	NEWA
>A>	AB			EQ 70MG BASE	N75871 005	Apr 22, 2009	Apr	NEWA

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

@ SANDOZ

100MG

N70268 001 Dec 31, 1985 Mar DISC

@

300MG

N70269 001 Dec 31, 1985 Mar DISC

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB	+	PAR PHARM	5MG	N70346 001	Jan 22, 1986	Jan	CTEC
AB		SIGMAPHARM LABS LLC	5MG	N79133 001	Jan 30, 2009	Jan	NEWA

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ SANDOZ

EQ 5MG ANHYDROUS;50MG

N73357 001 Nov 27, 1991 Mar DISC

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

>D>	AP		HOSPIRA	250MG/ML	N70888 001	Jun 16, 1988	Apr	DISC
>A>			@	250MG/ML	N70888 001	Jun 16, 1988	Apr	DISC

TABLET; ORAL

AMICAR

XANODYNE PHARM

1GM

N15197 002 Jun 24, 2004 Jan NEWA

AMINOPHYLLINE

INJECTABLE; INJECTION

>D>		AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%					
>D>	+	HOSPIRA	100MG/100ML	N88147	002	May 03, 1983	Apr DISC
>A>	@		100MG/100ML	N88147	002	May 03, 1983	Apr DISC
>D>	+		200MG/100ML	N88147	003	May 03, 1983	Apr DISC
>A>	@		200MG/100ML	N88147	003	May 03, 1983	Apr DISC

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

>D>	AB	ALPHAPHARM	200MG	N75188	001	Feb 24, 1999	Apr CAHN
>A>	AB	MYLAN	200MG	N75188	001	Feb 24, 1999	Apr CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>A>	AB	ALKEM	EQ 2.5MG BASE	N78925	001	May 04, 2009	Apr NEWA
>A>	AB		EQ 5MG BASE	N78925	002	May 04, 2009	Apr NEWA
>A>	AB		EQ 10MG BASE	N78925	003	May 04, 2009	Apr NEWA
	AB	GLENMARK GENERICS	EQ 2.5MG BASE	N78552	001	Apr 08, 2009	Mar NEWA
	AB		EQ 5MG BASE	N78552	002	Apr 08, 2009	Mar NEWA
	AB		EQ 10MG BASE	N78552	003	Apr 08, 2009	Mar NEWA
	AB	SYNTHON PHARMS	EQ 2.5MG BASE	N77080	001	Jun 27, 2007	Jan CAHN
	AB		EQ 5MG BASE	N77080	002	Jun 27, 2007	Jan CAHN
	AB		EQ 10MG BASE	N77080	003	Jun 27, 2007	Jan CAHN

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

>A>		TABLET; ORAL					
>A>		EXFORGE HCT					
>A>		NOVARTIS	5MG;12.5MG;160MG	N22314	001	Apr 30, 2009	Apr NEWA
>A>			5MG;25MG;160MG	N22314	002	Apr 30, 2009	Apr NEWA
>A>			10MG;12.5MG;160MG	N22314	003	Apr 30, 2009	Apr NEWA
>A>	+		10MG;25MG;320MG	N22314	005	Apr 30, 2009	Apr NEWA
>A>			10MG;25MG;160MG	N22314	004	Apr 30, 2009	Apr NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	APOTEX	250MG;EQ 125MG BASE	N65333	001	Feb 24, 2009	Feb NEWA
AB		500MG;EQ 125MG BASE	N65333	002	Feb 24, 2009	Feb NEWA

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLONIDINE HYDROCHLORIDE

AT	AKORN INC	EQ 0.5% BASE	N77764	001	Mar 12, 2009	Feb NEWA	
AT	+	IOPIDINE ALCON	EQ 0.5% BASE	N20258	001	Jul 30, 1993	Feb CFTG

ARMODAFINIL

TABLET; ORAL

NUVIGIL

CEPHALON

100MG

N21875 002 Mar 26, 2009 Mar CMFD

200MG

N21875 005 Mar 26, 2009 Mar NEWA

>A>	<u>ARTEMETHER; LUMEFANTRINE</u>					
>A>	TABLET; ORAL					
>A>	COARTEM					
>A>	NOVARTIS	20MG;120MG	N22268	001	Apr 07, 2009	Apr NEWA
	<u>ASPIRIN; BUTALBITAL; CAFFEINE</u>					
	TABLET; ORAL					
	BUTALBITAL, ASPIRIN AND CAFFEINE					
	@ SANDOZ	325MG;50MG;40MG	N86398	002	Apr 06, 1984	Mar DISC
	<u>ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE</u>					
	TABLET; ORAL					
	ORPHENGESIC					
	@ SOLCO HLTHCARE	385MG;30MG;25MG	N75141	001	May 29, 1998	Jan CAHN
	ORPHENGESIC FORTE					
	@ SOLCO HLTHCARE	770MG;60MG;50MG	N75141	002	May 29, 1998	Jan CAHN
	<u>ATRACURIUM BESYLATE</u>					
	INJECTABLE; INJECTION					
	ATRACURIUM BESYLATE					
	@ HOSPIRA	10MG/ML	N74740	001	Mar 28, 1997	Jan DISC
	ATRACURIUM BESYLATE PRESERVATIVE FREE					
	@ HOSPIRA	10MG/ML	N74741	001	Mar 28, 1997	Jan DISC
	<u>AZACITIDINE</u>					
	INJECTABLE; IV-SC					
	VIDAZA					
	+ CELGENE	100MG/VIAL	N50794	001	May 19, 2004	Mar CAHN
	<u>AZELASTINE HYDROCHLORIDE</u>					
	SPRAY, METERED; NASAL					
>D>	AZELASTINE HYDROCHLORIDE					
>A>	@ APOTEX INC	EQ 0.125MG BASE/SPRAY	N77954	001	Apr 30, 2009	Apr DISC
	<u>AZITHROMYCIN</u>					
	INJECTABLE; INJECTION					
	AZITHROMYCIN					
AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	N65506	001	Mar 24, 2009	Mar NEWA
	<u>BACLOFEN</u>					
	TABLET; ORAL					
	BACLOFEN					
>D>	AB	ALPHAPHARM	10MG	N77181	001	Jul 29, 2005 Apr CAHN
>D>	AB		20MG	N77121	002	Jul 29, 2005 Apr CAHN
>A>	AB	MYLAN	10MG	N77181	001	Jul 29, 2005 Apr CAHN
>A>	AB		20MG	N77121	002	Jul 29, 2005 Apr CAHN
	<u>BENZTROPINE MESYLATE</u>					
	INJECTABLE; INJECTION					
	COGENTIN					
>A>	+ LUNDBECK INC	1MG/ML	N12015	001		Apr CAHN
>D>	+ OVATION PHARMS	1MG/ML	N12015	001		Apr CAHN

>A>	<u>BENZYL ALCOHOL</u>								
>A>	LOTION; TOPICAL								
>A>	BENZYL ALCOHOL								
>A>		+	SCIELE PHARMA INC	5%	N22129	001	Apr 09, 2009	Apr	NEWA
 <u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE</u>									
OINTMENT; TOPICAL									
TACLONEX									
		+	LEO PHARM	0.064%;0.005%	N21852	001	Jan 09, 2006	Mar	CAHN
 <u>BETHANECHOL CHLORIDE</u>									
TABLET; ORAL									
BETHANECHOL CHLORIDE									
>A>	AA		SUN PHARM INDS INC	5MG	N40897	001	Apr 22, 2009	Apr	NEWA
>A>	AA			10MG	N40897	002	Apr 22, 2009	Apr	NEWA
>A>	AA			25MG	N40897	003	Apr 22, 2009	Apr	NEWA
>A>	AA			50MG	N40897	004	Apr 22, 2009	Apr	NEWA
 <u>BRIMONIDINE TARTRATE</u>									
SOLUTION/DROPS; OPHTHALMIC									
BRIMONIDINE TARTRATE									
>D>	AT		IVAX PHARMS	0.2%	N76372	001	Sep 10, 2004	Apr	CAHN
>A>	AT		TEVA PARENTERAL	0.2%	N76372	001	Sep 10, 2004	Apr	CAHN
 <u>BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>									
SYRUP; ORAL									
BROMFED-DM									
>D>	AA		BRIGHTON PHARMS INC	2MG/5ML;10MG/5ML;30MG/5ML	N89681	001	Dec 22, 1988	Apr	CAHN
>A>	AA		WOCKHARDT EU	2MG/5ML;10MG/5ML;30MG/5ML	N89681	001	Dec 22, 1988	Apr	CAHN
 <u>BUDESONIDE</u>									
SUSPENSION; INHALATION									
BUDESONIDE									
	AN		APOTEX	0.25MG/2ML	N78202	001	Mar 30, 2009	Mar	NEWA
	AN			0.5MG/2ML	N78202	002	Mar 30, 2009	Mar	NEWA
>D>	AN		IVAX PHARMS INC	0.25MG/2ML	N77519	001	Nov 18, 2008	Apr	CAHN
>D>	AN			0.5MG/2ML	N77519	002	Nov 18, 2008	Apr	CAHN
>A>	AN		TEVA PARENTERAL	0.25MG/2ML	N77519	001	Nov 18, 2008	Apr	CAHN
>A>	AN			0.5MG/2ML	N77519	002	Nov 18, 2008	Apr	CAHN
 <u>BUPROPION HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE; ORAL									
BUPROPION HYDROCHLORIDE									
	AB1		WATSON LABS	100MG	N79095	001	Mar 24, 2009	Mar	NEWA
	AB2			150MG	N79094	001	Mar 24, 2009	Mar	NEWA
	AB1			150MG	N79095	002	Mar 24, 2009	Mar	NEWA
	AB1			200MG	N79095	003	Mar 24, 2009	Mar	NEWA
 <u>BUSPIRONE HYDROCHLORIDE</u>									
TABLET; ORAL									
BUSPAR									
AB	+		BRISTOL MYERS SQUIBB	15MG	N18731	003	Apr 22, 1996	Feb	CRLD
			@	30MG	N18731	004	Apr 22, 1996	Feb	DISC
BUSPIRONE HYDROCHLORIDE									
AB			DR REDDYS LABS LTD	5MG	N78246	001	Feb 27, 2009	Feb	NEWA

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	10MG	N78246 002	Feb 27, 2009	Feb	NEWA
AB		15MG	N78246 003	Feb 27, 2009	Feb	NEWA
AB		30MG	N78246 004	Feb 27, 2009	Feb	NEWA
>A>	MYLAN	5MG	N75467 001	Feb 28, 2002	Apr	CAHN
>A>		7.5MG	N75467 002	Mar 28, 2001	Apr	CAHN
>A>		10MG	N75467 003	Feb 28, 2002	Apr	CAHN
>A>		15MG	N75467 004	Feb 28, 2002	Apr	CAHN
>D>	PAR PHARM	5MG	N75467 001	Feb 28, 2002	Apr	CAHN
>D>		7.5MG	N75467 002	Mar 28, 2001	Apr	CAHN
>D>		10MG	N75467 003	Feb 28, 2002	Apr	CAHN
>D>		15MG	N75467 004	Feb 28, 2002	Apr	CAHN
	@ SANDOZ	5MG	N75413 001	Mar 19, 2002	Mar	DISC
	@	10MG	N75413 002	Mar 19, 2002	Mar	DISC
	@	15MG	N75413 003	Mar 19, 2002	Mar	DISC

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

>A>	HIKMA FARMACEUTICA	1MG/ML	N78400 001	May 01, 2009	Apr	NEWA
>A>		2MG/ML	N78247 001	Apr 29, 2009	Apr	NEWA
>A>		2MG/ML	N78400 002	May 01, 2009	Apr	NEWA

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFFEINE CITRATE

>A>	PADDOCK LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N77233 001	Sep 21, 2006	Apr	CAHN
>D>	PHARMAFORCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N77233 001	Sep 21, 2006	Apr	CAHN

CALCITRIOL

CAPSULE; ORAL

ROCALTROL

AB	VALIDUS PHARMS	0.25UGM	N18044 001		Mar	CAHN
AB	+	0.5UGM	N18044 002		Mar	CAHN

OINTMENT; TOPICAL

VECTICAL

+	GALDERMA LABS LP	3UGM/GM	N22087 001	Jan 23, 2009	Jan	NEWA
---	------------------	---------	------------	--------------	-----	------

SOLUTION; ORAL

ROCALTROL

AA	+	VALIDUS PHARMS	1UGM/ML	N21068 001	Nov 20, 1998	Mar	CAHN
----	---	----------------	---------	------------	--------------	-----	------

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

>D>	CARACO	100MG	N77272 001	Dec 07, 2005	Apr	CAHN
>D>	AB	200MG	N77272 002	Dec 07, 2005	Apr	CAHN
>D>		300MG	N77272 003	Dec 07, 2005	Apr	CAHN
>D>		400MG	N77272 004	Dec 07, 2005	Apr	CAHN
>A>	TORRENT PHARMS	100MG	N77272 001	Dec 07, 2005	Apr	CAHN
>A>	AB	200MG	N77272 002	Dec 07, 2005	Apr	CAHN
>A>		300MG	N77272 003	Dec 07, 2005	Apr	CAHN
>A>		400MG	N77272 004	Dec 07, 2005	Apr	CAHN

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

AB	TORRENT PHARMS	100MG	N75712 001	Jul 05, 2001	Jan	CAHN
----	----------------	-------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	TARO	100MG	N78115 001	Mar 31, 2009	Mar	NEWA
AB		200MG	N78115 002	Mar 31, 2009	Mar	NEWA
AB		400MG	N78115 003	Mar 31, 2009	Mar	NEWA
	TEGRETOL-XR					
AB	NOVARTIS	100MG	N20234 001	Mar 25, 1996	Mar	CFTG
AB		200MG	N20234 002	Mar 25, 1996	Mar	CFTG
AB	+	400MG	N20234 003	Mar 25, 1996	Mar	CFTG

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN

	@ PFIZER	EQ 382MG BASE	N50435 001		Mar	DISC
--	----------	---------------	------------	--	-----	------

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

	@ SANDOZ	10MG;100MG	N73586 001	Jun 29, 1995	Mar	DISC
	@	25MG;100MG	N73587 001	Jun 29, 1995	Mar	DISC
	@	25MG;250MG	N73620 001	Jun 29, 1995	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

>D>	BX	KV PHARM	50MG;200MG	N76663 001	Jun 24, 2004	Apr	DISC
>A>		@	50MG;200MG	N76663 001	Jun 24, 2004	Apr	DISC

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

>D>	AP	+	PHARMACHEMIE	50MG/VIAL	N76162 001	Oct 14, 2004	Apr	CAHN
>D>	AP	+		150MG/VIAL	N76162 002	Oct 14, 2004	Apr	CAHN
>D>	AP	+		450MG/VIAL	N76162 003	Oct 14, 2004	Apr	CAHN
>A>	AP	+	WATSON LABS	50MG/VIAL	N76162 001	Oct 14, 2004	Apr	CAHN
>A>	AP	+		150MG/VIAL	N76162 002	Oct 14, 2004	Apr	CAHN
>A>	AP	+		450MG/VIAL	N76162 003	Oct 14, 2004	Apr	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	PHARMACHEMIE BV	EQ 50MG/5ML (10MG/ML)	N77679 001	Feb 25, 2009	Feb	NEWA
AP		EQ 450MG/45ML (10MG/ML)	N77679 003	Feb 25, 2009	Feb	NEWA
AP		EQ 150MG/15ML (10MG/ML)	N77679 002	Feb 25, 2009	Feb	NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

	@ SANDOZ	350MG	N81025 001	Apr 13, 1989	Mar	DISC
--	----------	-------	------------	--------------	-----	------

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	N65280 001	Mar 18, 2009	Mar	NEWA
AP		EQ 1GM BASE/VIAL	N65280 002	Mar 18, 2009	Mar	NEWA
AP		EQ 10GM BASE/VIAL	N65295 001	Mar 18, 2009	Mar	NEWA
AP		EQ 20GM BASE/VIAL	N65296 001	Mar 18, 2009	Mar	NEWA

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

@ GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N64033 001 Oct 31, 1993 Mar DISC

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

AP + SANDOZ

EQ 2GM BASE/VIAL

N65169 004 May 09, 2005 Mar CRLD

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

>A> AA

DR REDDYS LABS LTD

5MG/5ML

N78870 001 Apr 27, 2009 Apr NEWA

CHLOROTHIAZIDE

TABLET; ORAL

DIURIL

>A>

@ LUNDBECK INC

250MG

N11145 004

Apr CAHN

>A>

@

500MG

N11145 002

Apr CAHN

>D>

@ OVATION PHARMS

250MG

N11145 004

Apr CAHN

>D>

@

500MG

N11145 002

Apr CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

DIURIL

>A>

+ LUNDBECK INC

EQ 500MG BASE/VIAL

N11145 005

Apr CAHN

>D>

+ OVATION PHARMS

EQ 500MG BASE/VIAL

N11145 005

Apr CAHN

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ SANDOZ

100MG

N88725 001 Aug 31, 1984 Mar DISC

@

250MG

N88726 001 Aug 31, 1984 Mar DISC

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

@ SANDOZ

250MG

N89852 001 May 04, 1988 Mar DISC

@

500MG

N89853 001 May 04, 1988 Mar DISC

>D> AA

TEVA

500MG

N89859 001 May 04, 1988 Apr CAHN

>A> AA

WATSON LABS

500MG

N89859 001 May 04, 1988 Apr CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

TRILIPIX

ABBOTT LABS

EQ 45MG FENOFIBRIC ACID

N22224 001 Dec 15, 2008 Jan CTNA

+

EQ 135MG FENOFIBRIC ACID

N22224 002 Dec 15, 2008 Jan CTNA

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

@ CHART MEDCL

4,000 UNITS/VIAL

N18663 002 Aug 21, 1984 Mar CAHN

@

10,000 UNITS/VIAL

N18663 001 Nov 10, 1982 Mar CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ SANDOZ	200MG	N74100 001	Jan 31, 1995	Mar	DISC
@	300MG	N74100 002	Jan 31, 1995	Mar	DISC
@	400MG	N74100 003	Jan 31, 1995	Mar	DISC
@	800MG	N74100 004	Jan 31, 1995	Mar	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	MYLAN	EQ 250MG BASE	N75685 002	Jun 09, 2004	Mar	CMFD
AB		EQ 500MG BASE	N75685 003	Jun 09, 2004	Mar	CMFD
AB		EQ 750MG BASE	N75685 001	Jun 09, 2004	Mar	CMFD
	@ TEVA	EQ 250MG BASE	N76136 001	Jun 09, 2004	Jan	DISC
	@	EQ 500MG BASE	N76136 002	Jun 09, 2004	Jan	DISC
	@	EQ 750MG BASE	N76136 003	Jun 09, 2004	Jan	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	AMNEAL PHARMS	EQ 10MG BASE	N77045 003	Apr 29, 2005	Feb	CAHN
AB		EQ 20MG BASE	N77045 002	Apr 29, 2005	Feb	CAHN
AB		EQ 40MG BASE	N77045 001	Apr 29, 2005	Feb	CAHN
AB	GLENMARK GENERICS	EQ 10MG BASE	N77654 001	Feb 27, 2009	Feb	NEWA
AB		EQ 20MG BASE	N77654 002	Feb 27, 2009	Feb	NEWA
AB		EQ 40MG BASE	N77654 003	Feb 27, 2009	Feb	NEWA

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

@ SANDOZ	0.1MG	N70887 001	Aug 31, 1988	Mar	DISC
@	0.2MG	N70886 001	Aug 31, 1988	Mar	DISC
@	0.3MG	N71294 001	Aug 31, 1988	Mar	DISC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

@ SANDOZ	3.75MG	N72219 001	Aug 26, 1988	Mar	DISC
>A>	@ LUNDBECK INC	3.75MG	N17105 001		Apr CAHN
>A>	@	7.5MG	N17105 002		Apr CAHN
>A>	@	15MG	N17105 003		Apr CAHN
>D>	@ OVATION PHARMS	3.75MG	N17105 001		Apr CAHN
>D>	@	7.5MG	N17105 002		Apr CAHN
>D>	@	15MG	N17105 003		Apr CAHN

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ SANDOZ	7.5MG	N72513 001	May 11, 1990	Mar	DISC
@	15MG	N72514 001	May 11, 1990	Mar	DISC
>A>	AB LUNDBECK INC	3.75MG	N17105 006		Apr CAHN
>A>	AB	7.5MG	N17105 007		Apr CAHN
>A>	AB +	15MG	N17105 008		Apr CAHN
>D>	AB OVATION PHARMS	3.75MG	N17105 006		Apr CAHN

TABLET; ORAL

TRANXENE

>D>	AB	OVATION PHARMS	7.5MG	N17105 007		Apr	CAHN
>D>	AB	+	15MG	N17105 008		Apr	CAHN
<u>TRANXENE SD</u>							
>A>		LUNDBECK INC	11.25MG	N17105 005		Apr	CAHN
>A>		+	22.5MG	N17105 004		Apr	CAHN
>D>		OVATION PHARMS	11.25MG	N17105 005		Apr	CAHN
>D>		+	22.5MG	N17105 004		Apr	CAHN

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

>D>	+	STAT-TRADE	10MG/5ML;30MG/5ML;1.25MG/5ML	N88704 001	Mar 22, 1985	Apr	CAHN
>A>	+	STI PHARMA LLC	10MG/5ML;30MG/5ML;1.25MG/5ML	N88704 001	Mar 22, 1985	Apr	CAHN

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE

>D>	AP	PADDOCK	EQ 150MG BASE/VIAL	N65177 001	Mar 19, 2004	Apr	CTNA
>D>	AP	X GEN PHARMS	EQ 150MG BASE/VIAL	N64216 001	Feb 26, 1999	Apr	CTNA
<u>COLISTIMETHATE SODIUM</u>							
>A>	AP	PADDOCK	EQ 150MG BASE/VIAL	N65177 001	Mar 19, 2004	Apr	CTNA
>A>	AP	X GEN PHARMS	EQ 150MG BASE/VIAL	N64216 001	Feb 26, 1999	Apr	CTNA

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

>D>	AN	+	IVAX PHARMS	10MG/ML	N75271 001	Jan 18, 2000	Apr	CAHN
>A>	AN	+	TEVA PARENTERAL	10MG/ML	N75271 001	Jan 18, 2000	Apr	CAHN

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

@ PAR PHARM

0.5MG/INH

N19722 001 Nov 05, 1996 Mar CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

@ BAXTER HLTHCARE

100MG/VIAL

N12142 001

Feb CAHN

@

200MG/VIAL

N12142 002

Feb CAHN

@

500MG/VIAL

N12142 003

Feb CAHN

@

1GM/VIAL

N12142 004 Aug 30, 1982 Feb CAHN

@

2GM/VIAL

N12142 005 Aug 30, 1982 Feb CAHN

LYOPHILIZED CYTOXAN

+ BAXTER HLTHCARE

100MG/VIAL

N12142 006 Dec 05, 1985 Feb CAHN

+

200MG/VIAL

N12142 007 Dec 10, 1985 Feb CAHN

AP

+

500MG/VIAL

N12142 008 Jan 04, 1984 Feb CAHN

AP

+

1GM/VIAL

N12142 010 Sep 24, 1985 Feb CAHN

AP

+

2GM/VIAL

N12142 009 Dec 10, 1984 Feb CAHN

TABLET; ORAL

CYTOXAN

@ BAXTER HLTHCARE

25MG

N12141 002

Feb CAHN

@

50MG

N12141 001

Feb CAHN

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

>A>	+	LUNDBECK INC	0.5MG/VIAL	N50682 001		Apr	CAHN
>D>	+	OVATION PHARMS	0.5MG/VIAL	N50682 001		Apr	CAHN

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

>D>	AP	TEVA PARENTERAL	500MG/VIAL	N76806 001	Mar 31, 2006	Apr	CAHN
>D>	AP		2GM/VIAL	N76806 002	Mar 31, 2006	Apr	CAHN
>A>	AP	WATSON LABS	500MG/VIAL	N76806 001	Mar 31, 2006	Apr	CAHN
>A>	AP		2GM/VIAL	N76806 002	Mar 31, 2006	Apr	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGESTREL AND ETHINYL ESTRADIOL

@ DURAMED PHARMS BARR 0.15MG;0.03MG

N75256 001 Aug 12, 1999 Feb DISC

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

>D>	AA	+	STAT-TRADE	0.5MG/5ML	N84754 001		Apr	CAHN
>A>	AA	+	STI PHARMA LLC	0.5MG/5ML	N84754 001		Apr	CAHN

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX ST

+ ALCON 0.05%;0.3%

N50818 001 Feb 13, 2009 Feb NEWA

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

KAPIDEX

TAKEDA PHARMS 30MG

N22287 001 Jan 30, 2009 Jan NEWA

+ 60MG

N22287 002 Jan 30, 2009 Jan NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA + BARR 10MG

N40361 002 Jan 31, 2001 Mar CRLD

DEXTROSTAT

@ SHIRE 5MG

N84051 001 Mar DISC

@ 10MG

N84051 002 Mar DISC

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 60% IN PLASTIC CONTAINER

>D>	AP	+	HOSPIRA	60GM/100ML	N19346 001	Jan 25, 1985	Apr	DISC
-----	----	---	---------	------------	------------	--------------	-----	------

>A>		@		60GM/100ML	N19346 001	Jan 25, 1985	Apr	DISC
-----	--	---	--	------------	------------	--------------	-----	------

DIAZEPAM

TABLET; ORAL

DIAZEPAM

@ SANDOZ 2MG

N70302 001 Dec 20, 1985 Mar DISC

@ 5MG

N70303 001 Dec 20, 1985 Mar DISC

TABLET; ORAL

DIAZEPAM

@ SANDOZ	10MG	N70304 001	Dec 20, 1985	Mar	DISC
----------	------	------------	--------------	-----	------

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

AA	COREPHARMA	25MG	N40828 001	Nov 05, 2008	Feb	CTEC
----	------------	------	------------	--------------	-----	------

TENUATE

AA	+ WATSON PHARMS	25MG	N11722 002		Feb	CTEC
----	-----------------	------	------------	--	-----	------

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

@ SANDOZ	500MG	N74604 001	Jun 10, 1996	Mar	DISC
----------	-------	------------	--------------	-----	------

+ TEVA	500MG	N73673 001	Jul 31, 1992	Mar	CTEC
--------	-------	------------	--------------	-----	------

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

>D>	AP	HOSPIRA	0.25MG/ML	N40206 001	Aug 28, 1998	Apr	DISC
-----	----	---------	-----------	------------	--------------	-----	------

>A>		@	0.25MG/ML	N40206 001	Aug 28, 1998	Apr	DISC
-----	--	---	-----------	------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILT-CD

>A>	AB3	APOTEX	300MG	N76151 004	May 20, 2004	Apr	CAHN
-----	-----	--------	-------	------------	--------------	-----	------

>D>	AB3	TORPHARM	300MG	N76151 004	May 20, 2004	Apr	CAHN
-----	-----	----------	-------	------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+	BARR	50MG	N80738 001		Mar	CRLD
---	------	------	------------	--	-----	------

@ LNK	25MG	N87977 001	Jan 27, 1983	Mar	DISC
-------	------	------------	--------------	-----	------

@	50MG	N87978 001	Jan 27, 1983	Mar	DISC
---	------	------------	--------------	-----	------

@ SANDOZ	25MG	N80832 001		Mar	DISC
----------	------	------------	--	-----	------

@	50MG	N80832 002		Mar	DISC
---	------	------------	--	-----	------

@ VALEANT PHARM INTL	50MG	N80592 001		Mar	DISC
----------------------	------	------------	--	-----	------

@ WATSON LABS	25MG	N80728 001		Mar	DISC
---------------	------	------------	--	-----	------

@	50MG	N80727 001		Mar	DISC
---	------	------------	--	-----	------

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

@ SANDOZ	25MG	N86944 002	Apr 16, 1991	Mar	DISC
----------	------	------------	--------------	-----	------

@	50MG	N87562 001	Feb 25, 1992	Mar	DISC
---	------	------------	--------------	-----	------

@	75MG	N87561 001	Feb 25, 1992	Mar	DISC
---	------	------------	--------------	-----	------

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

AB	+ ABBOTT	EQ 125MG VALPROIC ACID	N19680 001	Sep 12, 1989	Jan	CFTG
----	----------	------------------------	------------	--------------	-----	------

DIVALPROEX SODIUM

AB	DR REDDYS LABS LTD	EQ 125MG VALPROIC ACID	N78979 001	Jan 23, 2009	Jan	NEWA
----	--------------------	------------------------	------------	--------------	-----	------

AB	ZYDUS PHARMS USA INC	EQ 125MG VALPROIC ACID	N78919 001	Jan 27, 2009	Jan	NEWA
----	----------------------	------------------------	------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB	MYLAN	EQ 125MG VALPROIC ACID	N90062 001	Mar 17, 2009	Mar	NEWA
AB		EQ 250MG VALPROIC ACID	N90062 002	Mar 17, 2009	Mar	NEWA
AB		EQ 500MG VALPROIC ACID	N90062 003	Mar 17, 2009	Mar	NEWA
AB	ZYDUS PHARMS USA INC	EQ 125MG VALPROIC ACID	N77100 001	Mar 05, 2009	Feb	NEWA
AB		EQ 250MG VALPROIC ACID	N77100 002	Mar 05, 2009	Feb	NEWA
AB		EQ 500MG VALPROIC ACID	N77100 003	Mar 05, 2009	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

DEPAKOTE ER

AB	ABBOTT	EQ 250MG VALPROIC ACID	N21168 002	May 31, 2002	Jan	CFTG
AB	+	EQ 500MG VALPROIC ACID	N21168 001	Aug 04, 2000	Jan	CFTG

DIVALPROEX SODIUM

AB	ANCHEN PHARMS	EQ 250MG VALPROIC ACID	N78445 001	Feb 26, 2009	Feb	NEWA
>A> AB	IMPAX LABS	EQ 250MG VALPROIC ACID	N78791 001	May 06, 2009	Apr	NEWA
AB	MYLAN	EQ 250MG VALPROIC ACID	N77567 001	Jan 29, 2009	Jan	NEWA
AB		EQ 500MG VALPROIC ACID	N77567 002	Jan 29, 2009	Jan	NEWA
AB	WOCKHARDT	EQ 250MG VALPROIC ACID	N78705 002	Feb 10, 2009	Jan	NEWA
AB	ZYDUS PHARMS USA INC	EQ 250MG VALPROIC ACID	N78239 001	Feb 27, 2009	Feb	NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	ALCON	EQ 2% BASE	N78981 001	Apr 13, 2009	Mar	NEWA
----	-------	------------	------------	--------------	-----	------

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

+	PAR PHARM	EQ 150MG BASE	N65055 003	Jul 15, 2005	Jan	CRLD
---	-----------	---------------	------------	--------------	-----	------

TABLET; ORAL

DOXYCYCLINE

AB	MUTUAL PHARM	EQ 50MG BASE	N65471 001	Apr 17, 2009	Mar	NEWA
AB		EQ 75MG BASE	N65471 002	Apr 17, 2009	Mar	NEWA
AB		EQ 100MG BASE	N65471 003	Apr 17, 2009	Mar	NEWA

DRONABINOL

CAPSULE; ORAL

DRONABINOL

AB	SVC PHARMA	2.5MG	N78292 001	Jun 27, 2008	Mar	CAHN
AB		5MG	N78292 002	Jun 27, 2008	Mar	CAHN
AB		10MG	N78292 003	Jun 27, 2008	Mar	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	BARR	3MG;0.02MG	N78515 001	Mar 30, 2009	Mar	NEWA	
	YAZ						
AB	+	BAYER HLTHCARE	3MG;0.02MG	N21676 001	Mar 16, 2006	Mar	CFTG

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@	SANDOZ	2.5MG	N75048 001	Aug 22, 2000	Mar	DISC
@		5MG	N75048 002	Aug 22, 2000	Mar	DISC
@		10MG	N75048 003	Aug 22, 2000	Mar	DISC
@		20MG	N75048 004	Aug 22, 2000	Mar	DISC

ENALAPRILAT

	INJECTABLE; INJECTION						
	ENALAPRILAT						
AP	+	HOSPIRA	1.25MG/ML	N75458	001	Aug 22, 2000	Feb CRLD
		VASOTEC					
		@ BIOVAIL LABS INTL	1.25MG/ML	N19309	001	Feb 09, 1988	Feb DISC

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
>D>		CITANEST FORTE					
>D>	+	DENTSPLY PHARM	0.005MG/ML;4%	N21383	001		Apr CTNA
>A>		CITANEST FORTE DENTAL					
>A>	+	DENTSPLY PHARM	0.005MG/ML;4%	N21383	001		Apr CTNA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
>A>		XYLOCAINE DENTAL WITH EPINEPHRINE					
>A>	AP	+	DENTSPLY PHARM	0.01MG/ML;2%	N21381	001	Apr CTNA
>A>	AP	+		0.02MG/ML;2%	N21381	002	Apr CTNA
		XYLOCAINE W/ EPINEPHRINE					
>D>		@ APP PHARMS	0.02MG/ML;2%	N06488	005		Apr CMFD
>A>	AP	+		0.02MG/ML;2%	N06488	005	Apr CMFD
>D>	AP	+	DENTSPLY PHARM	0.01MG/ML;2%	N21381	001	Apr CTNA
>D>	AP	+		0.02MG/ML;2%	N21381	002	Apr CTNA

EPOPROSTENOL SODIUM

	INJECTABLE; INJECTION						
	EPOPROSTENOL SODIUM						
>A>	+	ACTELION	EQ 1.5MG BASE/VIAL	N22260	001	Jun 27, 2008	Apr CAHN
>D>	+	GENERAMEDIX	EQ 1.5MG BASE/VIAL	N22260	001	Jun 27, 2008	Apr CAHN

>D>	<u>ERYTHROMYCIN ESTOLATE</u>						
>D>	SUSPENSION; ORAL						
>D>	ERYTHROMYCIN ESTOLATE						
>D>		ALPHARMA US PHARMS	EQ 125MG BASE/5ML	N62353	001	Nov 18, 1982	Apr DISC
>A>		@	EQ 125MG BASE/5ML	N62353	001	Nov 18, 1982	Apr DISC
>D>	+		EQ 250MG BASE/5ML	N62409	001	Dec 16, 1982	Apr DISC
>A>		@	EQ 250MG BASE/5ML	N62409	001	Dec 16, 1982	Apr DISC

ERYTHROMYCIN ETHYLSUCCINATE

	SUSPENSION; ORAL						
>D>	ERYTHROMYCIN ETHYLSUCCINATE						
>D>	AB	ALPHARMA US PHARMS	EQ 200MG BASE/5ML	N62200	001		Apr DISC
>A>		@	EQ 200MG BASE/5ML	N62200	001		Apr DISC
>D>	AB		EQ 400MG BASE/5ML	N62200	002		Apr DISC
>A>		@	EQ 400MG BASE/5ML	N62200	002		Apr DISC

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

	GRANULE; ORAL						
	ERYZOLE						
		@ ALRA	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N62758	001	Jun 15, 1988	Jan DISC
	PEDIAZOLE						
		@ ROSS LABS	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N50529	001		Jan DISC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

	@ HOSPIRA	EQ 1GM BASE/VIAL	N50182 003		Feb	DISC
AP	+	EQ 1GM BASE/VIAL	N62638 002	Oct 31, 1986	Feb	CRLD

ESTRADIOL

TABLET; ORAL

INNOFEM

>D>						
>D>	AB	NOVO NORDISK INC	0.5MG	N40312 001	Nov 19, 1999	Apr DISC
>A>		@	0.5MG	N40312 001	Nov 19, 1999	Apr DISC
>D>	AB		1MG	N40312 002	Nov 19, 1999	Apr DISC
>A>		@	1MG	N40312 002	Nov 19, 1999	Apr DISC
>D>	AB		2MG	N40312 003	Nov 19, 1999	Apr DISC
>A>		@	2MG	N40312 003	Nov 19, 1999	Apr DISC

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

AB		STI PHARMA LLC	100MG	N16320 001		Mar CAHN
		@	200MG	N16320 002		Mar CAHN
AB			400MG	N16320 003		Mar CAHN
		@	500MG	N16320 004		Mar CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

>D>		DEMULEN 1/35-21				
>D>	AB	+ GD SEARLE LLC	0.035MG;1MG	N18168 001		Apr DISC
>A>		@	0.035MG;1MG	N18168 001		Apr DISC
>D>		DEMULEN 1/50-21				
>D>	AB	+ GD SEARLE LLC	0.05MG;1MG	N16927 001		Apr DISC
>A>		@	0.05MG;1MG	N16927 001		Apr DISC
>D>		ZOVIA 1/35E-21				
>D>	AB	WATSON LABS	0.035MG;1MG	N72720 001	Dec 30, 1991	Apr DISC
>A>		@	0.035MG;1MG	N72720 001	Dec 30, 1991	Apr DISC
>D>		ZOVIA 1/50E-21				
>D>	AB	WATSON LABS	0.05MG;1MG	N72722 001	Dec 30, 1991	Apr DISC
>A>		@	0.05MG;1MG	N72722 001	Dec 30, 1991	Apr DISC

TABLET; ORAL-28

>D>		DEMULEN 1/35-28				
>D>	AB	+ GD SEARLE LLC	0.035MG;1MG	N18160 001		Apr DISC
>A>		@	0.035MG;1MG	N18160 001		Apr DISC
>D>		DEMULEN 1/50-28				
>D>	AB	GD SEARLE LLC	0.05MG;1MG	N16936 001		Apr DISC
>A>		@	0.05MG;1MG	N16936 001		Apr DISC
>D>		ZOVIA 1/50E-28				
>D>	AB	WATSON LABS	0.05MG;1MG	N72723 001	Dec 30, 1991	Apr CRLD
>A>		+	0.05MG;1MG	N72723 001	Dec 30, 1991	Apr CRLD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

TRIPHASIL-21

>A>		@ AKRIMAX PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N19192 001	Nov 01, 1984	Apr CAHN
-----	--	------------------	---	------------	--------------	----------

TABLET; ORAL-21

TRIPHASIL-21

>D>		@ WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N19192 001	Nov 01, 1984	Apr	CAHN
-----	--	--------------------	---	------------	--------------	-----	------

TABLET; ORAL-28

TRIPHASIL-28

>D>	AB	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N19190 001	Nov 01, 1984	Apr	DISC
>A>		@	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N19190 001	Nov 01, 1984	Apr	DISC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

>D>		+ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041 001	Sep 24, 1991	Apr	CRLD
>A>			0.035MG,0.035MG;0.5MG,1MG	N71041 001	Sep 24, 1991	Apr	CRLD

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

>D>	AB	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71044 001	Apr 01, 1988	Apr	CTEC
>A>			0.035MG,0.035MG;0.5MG,1MG	N71044 001	Apr 01, 1988	Apr	CTEC
		ORTHO-NOVUM 10/11-28					
		@ ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG	N18354 002	Jan 11, 1982	Mar	DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

LOESTRIN 21 1.5/30

>D>	AB	+ WARNER CHILCOTT	0.03MG;1.5MG	N17875 001		Apr	CRLD
>A>	AB		0.03MG;1.5MG	N17875 001		Apr	CRLD

LOESTRIN 21 1/20

>D>	AB	+ WARNER CHILCOTT	0.02MG;1MG	N17876 001		Apr	CRLD
>A>	AB		0.02MG;1MG	N17876 001		Apr	CRLD

TABLET; ORAL-28

LOESTRIN FE 1/20

>D>	AB	+ WARNER CHILCOTT	0.02MG;1MG	N17354 001		Apr	CRLD
>A>	AB		0.02MG;1MG	N17354 001		Apr	CRLD

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

OGESTREL 0.5/50-21

>D>		+ WATSON LABS	0.05MG;0.5MG	N75406 001	Dec 15, 1999	Apr	DISC
>A>		@	0.05MG;0.5MG	N75406 001	Dec 15, 1999	Apr	DISC

OVRAL

@ AKRIMAX PHARMS

			0.05MG;0.5MG	N16672 001		Mar	CAHN
--	--	--	--------------	------------	--	-----	------

ETHOTOIN

TABLET; ORAL

PEGANONE

>A>		+ LUNDBECK INC	250MG	N10841 001		Apr	CAHN
>A>		@	500MG	N10841 003		Apr	CAHN
>D>		+ OVATION PHARMS	250MG	N10841 001		Apr	CAHN
>D>		@	500MG	N10841 003		Apr	CAHN

ETOPOSID

CAPSULE; ORAL

ETOPOSID

		+ GENPHARM	50MG	N75635 001	Sep 19, 2001	Feb	CRLD
--	--	------------	------	------------	--------------	-----	------

CAPSULE; ORAL

VEPESID

@ BRISTOL MYERS SQUIBB 50MG

N19557 001 Dec 30, 1986 Feb DISC

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS 5MG

N22334 001 Mar 30, 2009 Mar NEWA

+ 10MG

N22334 002 Mar 30, 2009 Mar NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

@ SANDOZ 20MG

N75302 001 Apr 16, 2001 Mar DISC

@ 40MG

N75302 002 Apr 16, 2001 Mar DISC

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS 40MG

N21856 001 Feb 13, 2009 Feb NEWA

+ 80MG

N21856 002 Feb 13, 2009 Feb NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

@ PEDINOL EQ 300MG BASE

N17604 002 Feb DISC

NALFON 200

+ PEDINOL EQ 200MG BASE

N17604 003 Feb CRLD

TABLET; ORAL

FENOPROFEN CALCIUM

@ SANDOZ EQ 600MG BASE

N72396 001 Oct 17, 1988 Mar DISC

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

@ SANDOZ 50MG

N76030 001 Oct 28, 2002 Mar DISC

@ 100MG

N76030 002 Oct 28, 2002 Mar DISC

@ 150MG

N76030 003 Oct 28, 2002 Mar DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

AP ACTAVIS TOTOWA 50MG/VIAL

N78610 001 Feb 11, 2009 Feb NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP HIKMA FARMACEUTICA 0.5MG/5ML (0.1MG/ML)

N78527 001 Mar 23, 2009 Mar NEWA

AP 1MG/10ML (0.1MG/ML)

N78527 002 Mar 23, 2009 Mar NEWA

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

DERMA-SMOOTHIE/FS

+ HILL DERMAC 0.01%

N19452 002 Nov 09, 2005 Feb NEWA

FLUOROURACIL

SOLUTION; TOPICAL

FLUOROPLEX

@	ELORAC	1%	N16765	001			Feb	CAHN
---	--------	----	--------	-----	--	--	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1	ALEMBIC LTD	EQ 10MG BASE	N90223	001	Mar 19, 2009	Mar	NEWA
AB1		EQ 20MG BASE	N90223	002	Mar 19, 2009	Mar	NEWA
AB		EQ 40MG BASE	N90223	003	Mar 19, 2009	Mar	NEWA
AB1	BEIJING DOUBLE CRANE	EQ 10MG BASE	N76165	001	Feb 01, 2002	Mar	CAHN
AB1		EQ 20MG BASE	N76165	002	Feb 01, 2002	Mar	CAHN

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

AA	AUROBINDO PHARM	EQ 20MG BASE/5ML	N79209	001	Mar 20, 2009	Mar	NEWA
----	-----------------	------------------	--------	-----	--------------	-----	------

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AB	ALPHAPHARM	EQ 10MG BASE	N75755	001	Aug 02, 2001	Apr	CAHN
>D>	+		EQ 20MG BASE	N75755	002	Aug 02, 2001	Apr	CAHN
>A>	AB	MYLAN	EQ 10MG BASE	N75755	001	Aug 02, 2001	Apr	CAHN
>A>	+		EQ 20MG BASE	N75755	002	Aug 02, 2001	Apr	CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

@	SANDOZ	15MG	N71716	001	Jul 31, 1991	Mar	DISC
@		30MG	N71717	001	Jul 31, 1991	Mar	DISC

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

@	SANDOZ	50MG	N74448	001	Jul 28, 1995	Mar	DISC
@		100MG	N74448	002	Jul 28, 1995	Mar	DISC

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@	IVAX PHARMS	25MG	N75898	001	Mar 12, 2001	Mar	DISC
@		50MG	N75898	002	Mar 12, 2001	Mar	DISC
@		100MG	N75898	003	Mar 12, 2001	Mar	DISC

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

AP	GENERAMEDIX	1.5GM/1.5ML (1GM/ML)	N79033	001	Apr 07, 2009	Mar	NEWA
----	-------------	----------------------	--------	-----	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@	SANDOZ	10MG	N76188	001	Oct 08, 2004	Mar	DISC
@		20MG	N76188	002	Oct 08, 2004	Mar	DISC
@		40MG	N76188	003	Oct 08, 2004	Mar	DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

MONOPRIL-HCT

@	BRISTOL MYERS SQUIBB	10MG;12.5MG	N20286	002	Nov 30, 1994	Feb	DISC
@		20MG;12.5MG	N20286	001	Nov 30, 1994	Feb	DISC

GALANTAMINE HYDROBROMIDE

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

AA	ROXANE	4MG/ML	N78185	001	Jan 30, 2009	Jan	NEWA
AA	+ RAZADYNE						
AA	+ ORTHO MCNEIL JANSSEN	4MG/ML	N21224	001	Jun 22, 2001	Jan	CFTG

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

>D>	AB	ALPHAPHARM	EQ 4MG BASE	N77603	001	Aug 28, 2008	Apr	CAHN
>D>	AB		EQ 8MG BASE	N77603	002	Aug 28, 2008	Apr	CAHN
>D>	AB		EQ 12MG BASE	N77603	003	Aug 28, 2008	Apr	CAHN
>A>	AB	BEJING YABAO	EQ 4MG BASE	N77604	001	Feb 06, 2009	Apr	CAHN
>A>	AB		EQ 8MG BASE	N77604	002	Feb 06, 2009	Apr	CAHN
>A>	AB		EQ 12MG BASE	N77604	003	Feb 06, 2009	Apr	CAHN
>A>	AB	MYLAN	EQ 4MG BASE	N77603	001	Aug 28, 2008	Apr	CAHN
>A>	AB		EQ 8MG BASE	N77603	002	Aug 28, 2008	Apr	CAHN
>A>	AB		EQ 12MG BASE	N77603	003	Aug 28, 2008	Apr	CAHN
>D>	AB	PAR PHARM	EQ 4MG BASE	N77604	001	Feb 06, 2009	Apr	CAHN
	AB		EQ 4MG BASE	N77604	001	Feb 06, 2009	Jan	NEWA
>D>	AB		EQ 8MG BASE	N77604	002	Feb 06, 2009	Apr	CAHN
	AB		EQ 8MG BASE	N77604	002	Feb 06, 2009	Jan	NEWA
>D>	AB		EQ 12MG BASE	N77604	003	Feb 06, 2009	Apr	CAHN
	AB		EQ 12MG BASE	N77604	003	Feb 06, 2009	Jan	NEWA
	AB	ROXANE	EQ 4MG BASE	N77608	001	Feb 11, 2009	Jan	NEWA
	AB		EQ 8MG BASE	N77608	002	Feb 11, 2009	Jan	NEWA
	AB		EQ 12MG BASE	N77608	003	Feb 11, 2009	Jan	NEWA

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB	+ TEVA	5MG	N74388	003	Aug 29, 1995	Mar	CRLD
	MICRONASE						
	@ PHARMACIA AND UPJOHN	1.25MG	N17498	001	May 01, 1984	Mar	DISC
	@	2.5MG	N17498	002	May 01, 1984	Mar	DISC
	@	5MG	N17498	003	May 01, 1984	Mar	DISC

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA	WEST WARD	1MG	N40836	001	Mar 05, 2009	Feb	NEWA
AA		2MG	N40836	002	Mar 05, 2009	Feb	NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>A>	AP	SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N78534	001	Apr 30, 2009	Apr	NEWA
>A>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N78531	001	Apr 30, 2009	Apr	NEWA
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N78531	002	Apr 30, 2009	Apr	NEWA

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

AB		DR REDDYS LABS LTD	EQ 1MG BASE	N78846	001	Feb 27, 2009	Feb	NEWA
----	--	--------------------	-------------	--------	-----	--------------	-----	------

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

>D>	AO	SANDOZ	EQ 50MG BASE/ML	N76463	001	Jun 24, 2005	Apr	DISC
>A>		@	EQ 50MG BASE/ML	N76463	001	Jun 24, 2005	Apr	DISC
>D>	AO		EQ 100MG BASE/ML	N76463	002	Jun 24, 2005	Apr	DISC
>A>		@	EQ 100MG BASE/ML	N76463	002	Jun 24, 2005	Apr	DISC

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

>D>	AP	SANDOZ	EQ 5MG BASE/ML	N76464	001	Sep 29, 2004	Apr	DISC
>A>		@	EQ 5MG BASE/ML	N76464	001	Sep 29, 2004	Apr	DISC

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

>D>	AP	HOSPIRA	10 UNITS/ML	N88346	001	May 18, 1983	Apr	DISC
>A>		@	10 UNITS/ML	N88346	001	May 18, 1983	Apr	DISC

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

>A>	+	ENDO PHARM	50MG	N22058	001	May 03, 2007	Apr	CAHN
>D>	+	INDEVUS	50MG	N22058	001	May 03, 2007	Apr	CAHN
		VANTAS						
>A>	+	ENDO PHARM	50MG	N21732	001	Oct 12, 2004	Apr	CAHN
>D>	+	ENDO PHARMS	50MG	N21732	001	Oct 12, 2004	Apr	CAHN
	+		50MG	N21732	001	Oct 12, 2004	Mar	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

@	ENDO PHARMS	1.5MG/5ML;5MG/5ML
---	-------------	-------------------

N05213	002	Jul 26, 1988	Feb	DISC
--------	-----	--------------	-----	------

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	+	HI TECH PHARMA	1.5MG/5ML;5MG/5ML	N40613	001	Feb 08, 2008	Feb	CRLD
----	---	----------------	-------------------	--------	-----	--------------	-----	------

TABLET; ORAL

HYCODAN

@	ENDO PHARMS	1.5MG;5MG
---	-------------	-----------

N05213	001	Jul 26, 1988	Feb	DISC
--------	-----	--------------	-----	------

TUSSIGON

AA	+	KING PHARMS	1.5MG;5MG	N88508	001	Jul 30, 1985	Feb	CRLD
----	---	-------------	-----------	--------	-----	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		AKORN	20MG/ML	N40730	001	Apr 21, 2009	Mar	NEWA
----	--	-------	---------	--------	-----	--------------	-----	------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@	SANDOZ	10MG
---	--------	------

N83241	001		Mar	DISC
--------	-----	--	-----	------

@		25MG
---	--	------

N83560	001		Mar	DISC
--------	-----	--	-----	------

@		50MG
---	--	------

N83561	001		Mar	DISC
--------	-----	--	-----	------

HYDROCHLOROTHIAZIDE

	CAPSULE; ORAL						
	HYDROCHLOROTHIAZIDE						
AB	IPCA LABS LTD	12.5MG	N79237	001	Apr 02, 2009	Mar	NEWA
	SOLUTION; ORAL						
	HYDROCHLOROTHIAZIDE						
	@ ROXANE	50MG/5ML	N88587	001	Jul 02, 1984	Mar	DISC
	TABLET; ORAL						
	HYDROCHLOROTHIAZIDE						
	@ SANDOZ	25MG	N87565	001	Mar 09, 1982	Mar	DISC
	@	50MG	N84912	001		Mar	DISC

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

	TABLET; ORAL						
	PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
	@ SANDOZ	25MG;40MG	N71060	001	Aug 26, 1987	Mar	DISC
	@	25MG;80MG	N71061	001	Aug 26, 1987	Mar	DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

	TABLET; ORAL						
	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
AB	RANBAXY	12.5MG;EQ 10MG BASE	N78211	001	Mar 04, 2009	Feb	NEWA
AB		12.5MG;EQ 20MG BASE	N78211	002	Mar 04, 2009	Feb	NEWA
AB		25MG;EQ 20MG BASE	N78211	003	Mar 04, 2009	Feb	NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

	TABLET; ORAL						
	SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE						
	@ SANDOZ	25MG;25MG	N86881	001		Mar	DISC

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

	SUSPENSION; OPHTHALMIC						
	TERRA-CORTRIL						
	@ PFIZER	1.5%;EQ 5MG BASE/ML	N61016	001		Feb	DISC

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

	AEROSOL, METERED; TOPICAL						
	PROCTOFOAM HC						
>D>	BX	SCHWARZ PHARMA	1%;1%	N86195	001	Apr	CAHN
>A>	BX	UCB INC	1%;1%	N86195	001	Apr	CAHN

HYDROCORTISONE ACETATE; UREA

	CREAM; TOPICAL						
	CARMOL HC						
>D>	AT	+ KENWOOD LABS	1%;10%	N80505	001	Apr	CAHN
>A>	AT	+ NYCOMED US	1%;10%	N80505	001	Apr	CAHN

HYDROMORPHONE HYDROCHLORIDE

	INJECTABLE; INJECTION							
	DILAUDID							
>A>		PURDUE PHARM PRODS	1MG/ML	N19034	003	Apr 30, 2009	Apr	NEWA
>A>			2MG/ML	N19034	004	Apr 30, 2009	Apr	NEWA
>A>			4MG/ML	N19034	005	Apr 30, 2009	Apr	NEWA

HYDROXYUREACAPSULE; ORAL
HYDROXYUREA

AB	BARR	500MG	N75143 001	Oct 16, 1998	Feb	CMFD
----	------	-------	------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDETABLET; ORAL
HYDROXYZINE HYDROCHLORIDE

	@ SANDOZ	10MG	N87869 001	Dec 20, 1982	Mar	DISC
	@	25MG	N87870 001	Dec 20, 1982	Mar	DISC
	@	50MG	N87871 001	Dec 20, 1982	Mar	DISC

HYDROXYZINE PAMOATECAPSULE; ORAL
HYDROXYZINE PAMOATE

	@ SANDOZ	EQ 25MG HCL	N81127 001	Jun 28, 1991	Mar	DISC
--	----------	-------------	------------	--------------	-----	------

IBUPROFENTABLET; ORAL
IBUPROFEN

AB	+	DR REDDYS LA	800MG	N75682 003	Nov 14, 2001	Feb	CRLD
		@ SANDOZ	300MG	N70734 001	Jun 12, 1986	Mar	DISC
		@	400MG	N70735 001	Jun 12, 1986	Mar	DISC
		@	600MG	N70736 001	Jun 12, 1986	Mar	DISC
		@	800MG	N72169 001	Dec 11, 1987	Mar	DISC
AB		SHASUN USA	400MG	N78329 001	Feb 05, 2009	Jan	NEWA
AB			600MG	N78329 002	Feb 05, 2009	Jan	NEWA
AB			800MG	N78329 003	Feb 05, 2009	Jan	NEWA

>D>		MOTRIN					
>D>		MCNEIL CONSUMER	300MG	N17463 003		Apr	DISC
>A>		@	300MG	N17463 003		Apr	DISC
		@	400MG	N17463 002		Feb	DISC
		@	600MG	N17463 004		Feb	DISC
		@	800MG	N17463 005	May 22, 1985	Feb	DISC

IBUPROFEN LYSINEINJECTABLE; INTRAVENOUS
NEOPROFEN

>A>	+	LUNDBECK INC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N21903 001	Apr 13, 2006	Apr	CAHN
>D>	+	OVATION PHARMS	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N21903 001	Apr 13, 2006	Apr	CAHN

IFOSFAMIDEINJECTABLE; INJECTION
IFEX

	@ BAXTER HLTHCARE	1GM/VIAL	N19763 001	Dec 30, 1988	Feb	CAHN
	@	3GM/VIAL	N19763 002	Dec 30, 1988	Feb	CAHN

IFOSFAMIDE; MESNAINJECTABLE; INJECTION
IFEX/MESNEX KIT

+	BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N19763 003	Oct 10, 1992	Feb	CAHN
+		3GM/VIAL;100MG/ML	N19763 004	Oct 10, 1992	Feb	CAHN

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

AB + SANDOZ 75MG N74464 001 May 28, 1998 Feb CTEC

INDOMETHACIN

AB AVANTHI INC 75MG N79175 001 Mar 06, 2009 Feb NEWA

SUSPENSION; ORAL

INDOCIN

+ IROKO PHARMS 25MG/5ML N18332 001 Oct 10, 1985 Mar CAHN

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

>A> AP + LUNDBECK INC EQ 1MG BASE/VIAL N18878 001 Jan 30, 1985 Apr CAHN

>D> AP + OVATION PHARMS EQ 1MG BASE/VIAL N18878 001 Jan 30, 1985 Apr CAHN

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

SANOFI AVENTIS US 300 UNITS/3ML N21629 003 Feb 24, 2009 Feb NEWA

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>D> AN IVAX PHARMS 0.02% N75313 001 Feb 07, 2000 Apr CAHN

>A> AN TEVA PARENTERAL 0.02% N75313 001 Feb 07, 2000 Apr CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP PHARMAFORCE 40MG/2ML (20MG/ML) N90016 001 Jan 28, 2009 Mar NEWA

AP 40MG/2ML(20MG/ML) N90016 001 Jan 28, 2009 Jan NEWA

AP 100MG/5ML (20MG/ML) N90016 002 Jan 28, 2009 Mar NEWA

AP 100MG/5ML(20MG/ML) N90016 002 Jan 28, 2009 Jan NEWA

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@ SANDOZ 2.5MG N86225 001 Feb 19, 1988 Mar DISC

@ 5MG N86222 001 Feb 19, 1988 Mar DISC

KETOCONAZOLE

GEL; TOPICAL

XOLEGEL

+ STIEFEL LABS INC 2% N21946 001 Jul 28, 2006 Jan CAHN

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

@ SANDOZ 50MG N74024 001 Dec 29, 1995 Mar DISC

@ 75MG N74024 002 Dec 29, 1995 Mar DISC

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	APOTEX INC	25MG	N78625 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78625 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78625 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78625 004	Jan 27, 2009	Jan	NEWA
AB	AUROBINDO PHARMA	25MG	N78956 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78956 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78956 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78956 004	Jan 27, 2009	Jan	NEWA
AB	CADISTA PHARMS	25MG	N79132 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N79132 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N79132 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N79132 004	Jan 27, 2009	Jan	NEWA
AB	DR REDDYS LABS LTD	25MG	N76708 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N76708 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N76708 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N76708 004	Jan 27, 2009	Jan	NEWA
AB	GENPHARM ULC	25MG	N77428 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77428 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77428 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77428 004	Jan 27, 2009	Jan	NEWA
AB	MATRIX LABS LTD	25MG	N78443 001	Feb 11, 2009	Jan	NEWA
AB		100MG	N78443 002	Feb 11, 2009	Jan	NEWA
AB		150MG	N78443 003	Feb 11, 2009	Jan	NEWA
AB		200MG	N78443 004	Feb 11, 2009	Jan	NEWA
AB	MYLAN	25MG	N77420 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77420 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77420 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77420 004	Jan 27, 2009	Jan	NEWA
AB	ROXANE	25MG	N77392 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77392 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77392 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77392 004	Jan 27, 2009	Jan	NEWA
AB	SANDOZ	25MG	N78645 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78645 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78645 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78645 004	Jan 27, 2009	Jan	NEWA
AB	TARO PHARM INDS	25MG	N78525 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78525 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78525 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78525 004	Jan 27, 2009	Jan	NEWA
AB	TORRENT PHARMS	25MG	N78947 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78947 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78947 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78947 004	Jan 27, 2009	Jan	NEWA
AB	UPSHER SMITH	25MG	N78310 001	Feb 04, 2009	Jan	NEWA
AB		100MG	N78310 002	Feb 04, 2009	Jan	NEWA
AB		150MG	N78310 003	Feb 04, 2009	Jan	NEWA
AB		200MG	N78310 004	Feb 04, 2009	Jan	NEWA
AB	WOCKHARDT	25MG	N78982 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78982 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78982 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78982 004	Jan 27, 2009	Jan	NEWA

TABLET; ORAL

LAMOTRIGINE

AB	ZYDUS PHARMS USA	25MG	N77633 001	Jan 27, 2009	Jan	NEWA
		50MG	N77633 002	Jan 27, 2009	Jan	NEWA
AB		100MG	N77633 003	Jan 27, 2009	Jan	NEWA
AB		150MG	N77633 004	Jan 27, 2009	Jan	NEWA
AB		200MG	N77633 005	Jan 27, 2009	Jan	NEWA
		250MG	N77633 006	Jan 27, 2009	Jan	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	5MG	N79099 001	Feb 19, 2009	Feb	NEWA
AB		25MG	N79099 002	Feb 19, 2009	Feb	NEWA
AB	TARO	5MG	N79204 001	Feb 04, 2009	Jan	NEWA
AB		25MG	N79204 002	Feb 04, 2009	Jan	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

AP	SUN PHARMA GLOBAL	1MG/0.2ML	N78885 001	Mar 09, 2009	Feb	NEWA
----	-------------------	-----------	------------	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	DEY	EQ 0.25% BASE	N78309 001	Mar 20, 2009	Mar	NEWA
	XOPENEX					
AN	+ SEPRACOR	EQ 0.25% BASE	N20837 004	Jul 18, 2003	Mar	CFTG

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

AA	SILARX	100MG/ML	N90263 001	Apr 03, 2009	Mar	NEWA
AA	TARO	100MG/ML	N78774 001	Feb 10, 2009	Jan	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	APOTEX INC	250MG	N78869 001	Mar 13, 2009	Mar	NEWA	
AB		500MG	N78869 002	Mar 13, 2009	Mar	NEWA	
AB		750MG	N78869 003	Mar 13, 2009	Mar	NEWA	
AB		1GM	N78869 004	Mar 13, 2009	Mar	NEWA	
AB	CIPLA LTD	250MG	N77319 001	Mar 20, 2009	Mar	NEWA	
AB		500MG	N77319 002	Mar 20, 2009	Mar	NEWA	
AB		750MG	N77319 003	Mar 20, 2009	Mar	NEWA	
AB	GENPHARM ULC	250MG	N78731 001	Feb 10, 2009	Jan	NEWA	
AB		500MG	N78731 002	Feb 10, 2009	Jan	NEWA	
AB		750MG	N78731 003	Feb 10, 2009	Jan	NEWA	
AB		1GM	N78731 004	Feb 10, 2009	Jan	NEWA	
AB	SOLCO HLTHCARE	250MG	N78106 001	Feb 10, 2009	Jan	NEWA	
AB		500MG	N78106 002	Feb 10, 2009	Jan	NEWA	
AB		750MG	N78106 003	Feb 10, 2009	Jan	NEWA	
AB		1GM	N78106 004	Feb 10, 2009	Jan	NEWA	
AB	WATSON LABS FLORIDA	250MG	N77408 001	Mar 02, 2009	Feb	NEWA	
AB		500MG	N77408 002	Mar 02, 2009	Feb	NEWA	
AB		750MG	N77408 003	Mar 02, 2009	Feb	NEWA	
>A>	AB	ZYDUS PHARMS USA INC	250MG	N78918 001	Apr 29, 2009	Apr	NEWA
>A>	AB		1GM	N78918 002	Apr 29, 2009	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

	UCB INC	500MG	N22285 001	Sep 12, 2008	Feb	CRLD
+		750MG	N22285 002	Feb 12, 2009	Feb	NEWA

LEVOFLOXACIN

TABLET; ORAL

LEVAQUIN

>D>		ORTHO MCNEIL JANSSEN	250MG	N20634 001	Dec 20, 1996	Apr	CFTG
>A>	AB		250MG	N20634 001	Dec 20, 1996	Apr	CFTG
>D>			500MG	N20634 002	Dec 20, 1996	Apr	CFTG
>A>	AB		500MG	N20634 002	Dec 20, 1996	Apr	CFTG
>D>		+	750MG	N20634 003	Sep 08, 2000	Apr	CFTG
>A>	AB	+	750MG	N20634 003	Sep 08, 2000	Apr	CFTG
>A>		LEVOFLOXACIN					
>A>	AB	LUPIN	250MG	N78424 001	May 13, 2009	Apr	NEWA
>A>	AB		500MG	N78424 002	May 13, 2009	Apr	NEWA
>A>	AB		750MG	N78424 003	May 13, 2009	Apr	NEWA

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVOTHYROXINE SODIUM

>D>	AB2, AB3	GENPHARM	0.025MG	N76752 001	Jun 16, 2005	Apr	CAHN
>D>	AB2, AB3		0.05MG	N76752 002	Jun 16, 2005	Apr	CAHN
>D>	AB2, AB3		0.075MG	N76752 003	Jun 16, 2005	Apr	CAHN
>D>	AB2, AB3		0.088MG	N76752 004	Jun 16, 2005	Apr	CAHN
>D>	AB2, AB3		0.1MG	N76752 005	Jun 16, 2005	Apr	CAHN
>D>	AB2, AB3		0.112MG	N76752 006	Jun 16, 2005	Apr	CAHN
>D>	AB2, AB3		0.125MG	N76752 007	Jun 16, 2005	Apr	CAHN
>D>	AB2, AB3		0.15MG	N76752 008	Jun 16, 2005	Apr	CAHN
>D>	AB2, AB3		0.175MG	N76752 009	Jun 16, 2005	Apr	CAHN
>D>	AB2, AB3		0.2MG	N76752 010	Jun 16, 2005	Apr	CAHN
>D>	AB2, AB3		0.3MG	N76752 011	Jun 16, 2005	Apr	CAHN
>A>	AB2, AB3	MERCK KGAA	0.025MG	N76752 001	Jun 16, 2005	Apr	CAHN
>A>	AB2, AB3		0.05MG	N76752 002	Jun 16, 2005	Apr	CAHN
>A>	AB2, AB3		0.075MG	N76752 003	Jun 16, 2005	Apr	CAHN
>A>	AB2, AB3		0.088MG	N76752 004	Jun 16, 2005	Apr	CAHN
>A>	AB2, AB3		0.1MG	N76752 005	Jun 16, 2005	Apr	CAHN
>A>	AB2, AB3		0.112MG	N76752 006	Jun 16, 2005	Apr	CAHN
>A>	AB2, AB3		0.125MG	N76752 007	Jun 16, 2005	Apr	CAHN
>A>	AB2, AB3		0.15MG	N76752 008	Jun 16, 2005	Apr	CAHN
>A>	AB2, AB3		0.175MG	N76752 009	Jun 16, 2005	Apr	CAHN
>A>	AB2, AB3		0.2MG	N76752 010	Jun 16, 2005	Apr	CAHN

TABLET; ORAL

LEVOTHYROXINE SODIUM

>A>	AB2, AB3	MERCK KGAA	0.3MG	N76752 011	Jun 16, 2005	Apr	CAHN
-----	-------------	------------	-------	------------	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

>D>	AP	HOSPIRA	10%	N88367 001	Jul 31, 1984	Apr	DISC
>A>		@	10%	N88367 001	Jul 31, 1984	Apr	DISC

XYLOCAINE

>D>		@ APP PHARMS	2%	N06488 002		Apr	CMFD
>A>	AP	+	2%	N06488 002		Apr	CMFD
>D>	AP	+	DENTSPLY PHARM	N21380 001		Apr	CTNA
>A>		XYLOCAINE DENTAL					
>A>	AP	+	DENTSPLY PHARM	N21380 001		Apr	CTNA

LINDANE

LOTION; TOPICAL

LINDANE

>D>		@ AL AND S	1%	N87313 001		Apr	CAHN
>A>		@ OLTA PHARMS	1%	N87313 001		Apr	CAHN

SHAMPOO; TOPICAL

LINDANE

AT	+	OLTA PHARMS	1%	N87266 001		Jan	CAHN
----	---	-------------	----	------------	--	-----	------

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB		KING PHARMS	EQ 0.005MG BASE	N10379 001		Mar	CFTG
AB			EQ 0.025MG BASE	N10379 002		Mar	CTEC
AB	+		EQ 0.05MG BASE	N10379 003		Mar	CTEC

LIOTHYRONINE SODIUM

AB		COASTAL PHARMS	EQ 0.005MG BASE	N90097 001	Mar 20, 2009	Mar	NEWA
AB			EQ 0.025MG BASE	N90097 002	Mar 20, 2009	Mar	NEWA
AB			EQ 0.05MG BASE	N90097 003	Mar 20, 2009	Mar	NEWA

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB		GLENMARK GENERICS	150MG	N79139 001	Feb 03, 2009	Jan	NEWA
AB			300MG	N79139 002	Feb 03, 2009	Jan	NEWA
AB			600MG	N79139 003	Feb 03, 2009	Jan	NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

		@ SANDOZ	2MG	N72993 001	Aug 28, 1992	Mar	DISC
--	--	----------	-----	------------	--------------	-----	------

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

>A>		PADDOCK LABS	2MG/ML	N79244 001	Apr 28, 2009	Apr	NEWA
>A>	AA						
		LORAZEPAM INTENSOL					
>D>		+ ROXANE	2MG/ML	N72755 001	Jun 28, 1991	Apr	CFTG
>A>	AA	+	2MG/ML	N72755 001	Jun 28, 1991	Apr	CFTG

SOLUTION; ORAL

LORAZEPAM

@ ROXANE

0.5MG/5ML

N74648 001 Mar 18, 1997 Mar DISC

MALATHION

LOTION; TOPICAL

MALATHION

AT SYNERX PHARMA

0.5%

N78743 001 Mar 06, 2009 Feb NEWA

OVIDE

AT + TARO PHARMS NORTH

0.5%

N18613 001 Aug 02, 1982 Feb CFTG

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

MUSTARGEN

>A> + LUNDBECK INC

10MG/VIAL

N06695 001

Apr CAHN

>D> + OVATION PHARMS

10MG/VIAL

N06695 001

Apr CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

AA + PFIZER

12.5MG

N10721 006

Jan CAHN

AA +

25MG

N10721 004

Jan CAHN

AA +

50MG

N10721 001 Jan 20, 1982 Jan CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

@ SANDOZ

EQ 50MG BASE

N72262 001 Nov 29, 1988 Mar DISC

@

EQ 100MG BASE

N72263 001 Nov 29, 1988 Mar DISC

MELOXICAM

TABLET; ORAL

MELOXICAM

>A> AB BEJING YABAO

7.5MG

N77933 001 Jul 19, 2006 Apr CAHN

>A> AB

15MG

N77933 002 Jul 19, 2006 Apr CAHN

>D> AB PAR PHARM

7.5MG

N77933 001 Jul 19, 2006 Apr CAHN

>D> AB

15MG

N77933 002 Jul 19, 2006 Apr CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

AA ALEMBIC LTD

200MG

N90122 001 Feb 18, 2009 Feb NEWA

AA

400MG

N90122 002 Feb 18, 2009 Feb NEWA

>A> @ IVC INDS

400MG

N84153 001

Apr CAHN

>D> @ PHARMERAL

400MG

N84153 001

Apr CAHN

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+ STIEFEL LABS INC

2%;0.01%

N20922 001 Dec 10, 1999 Jan CAHN

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/50M-21

>D>

>D> AB

WATSON LABS

0.05MG;1MG

N71539 001 Apr 12, 1988 Apr DISC

>A>

@

0.05MG;1MG

N71539 001 Apr 12, 1988 Apr DISC

TABLET; ORAL-21

NORETHINDRONE AND MESTRANOL

>D>	AB	WATSON LABS	0.05MG;1MG	N70758 001	Jul 01, 1988	Apr	DISC
>A>		@	0.05MG;1MG	N70758 001	Jul 01, 1988	Apr	DISC
>D>		NORINYL 1+50 21-DAY					
>D>	AB	+ WATSON LABS	0.05MG;1MG	N13625 002		Apr	DISC
>A>		@	0.05MG;1MG	N13625 002		Apr	DISC

TABLET; ORAL-28

NORETHIN 1/50M-28

>D>	AB	WATSON LABS	0.05MG;1MG	N71540 001	Apr 12, 1988	Apr	DISC
>A>		@	0.05MG;1MG	N71540 001	Apr 12, 1988	Apr	DISC

NORETHINDRONE AND MESTRANOL

>D>	AB	WATSON LABS	0.05MG;1MG	N70759 001	Jul 01, 1988	Apr	DISC
>A>		@	0.05MG;1MG	N70759 001	Jul 01, 1988	Apr	DISC

NORINYL 1+50 28-DAY

>D>	AB	WATSON LABS	0.05MG;1MG	N16659 001		Apr	CRLD
>A>		+	0.05MG;1MG	N16659 001		Apr	CRLD

ORTHO-NOVUM 1/50 28

>D>	AB	ORTHO MCNEIL JANSSEN	0.05MG;1MG	N16709 001		Apr	DISC
>A>		@	0.05MG;1MG	N16709 001		Apr	DISC

METAPROTERENOL SULFATE

SOLUTION; INHALATION

ALUPENT

	@	BOEHRINGER INGELHEIM	0.4%	N18761 002	Oct 10, 1986	Feb	DISC
	@		0.6%	N18761 001	Jun 30, 1983	Feb	DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

	AB	ALVOGEN	500MG	N76033 001	Jan 24, 2002	Jan	CAHN
	AB		850MG	N76033 002	Jan 24, 2002	Jan	CAHN
	AB		1GM	N76033 003	Jan 24, 2002	Jan	CAHN
>D>	AB	AMNEAL PHARM	500MG	N77853 001	Jul 28, 2006	Apr	CAHN
>D>	AB		850MG	N77853 002	Jul 28, 2006	Apr	CAHN
>D>	AB		1GM	N77853 003	Jul 28, 2006	Apr	CAHN
>A>	AB	PROVIDENT PHARM	500MG	N77853 001	Jul 28, 2006	Apr	CAHN
>A>	AB		850MG	N77853 002	Jul 28, 2006	Apr	CAHN
>A>	AB		1GM	N77853 003	Jul 28, 2006	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

	@	SANDOZ	500MG	N76223 001	Dec 14, 2004	Mar	DISC
--	---	--------	-------	------------	--------------	-----	------

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

>A>	+	LUNDBECK INC	5MG	N05378 002		Apr	CAHN
>D>	+	OVATION PHARMS	5MG	N05378 002		Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

DESOXYN

>A>	@	LUNDBECK INC	5MG	N05378 004		Apr	CAHN
>A>	@		10MG	N05378 003		Apr	CAHN
>A>	@		15MG	N05378 005		Apr	CAHN
>D>	@	OVATION PHARMS	5MG	N05378 004		Apr	CAHN
>D>	@		10MG	N05378 003		Apr	CAHN
>D>	@		15MG	N05378 005		Apr	CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

@ SOLCO HLTHCARE	500MG	N86989 001		Jan	CAHN
@	750MG	N86988 001		Jan	CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	EBEWE PARENTA	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	N90039 001	Mar 31, 2009	Mar	NEWA
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	N90039 002	Mar 31, 2009	Mar	NEWA
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N90029 001	Mar 31, 2009	Mar	NEWA

METHYLCLOTHIAZIDE

TABLET; ORAL

ENDURON

ABBOTT	2.5MG	N12524 001			Mar	CTEC
--------	-------	------------	--	--	-----	------

METHYLCLOTHIAZIDE

@ SANDOZ	2.5MG	N89835 001	Aug 18, 1988	Mar	DISC
@	5MG	N89837 001	Aug 18, 1988	Mar	DISC

METHYLDOPA

TABLET; ORAL

METHYLDOPA

@ SANDOZ	125MG	N71700 001	Mar 02, 1988	Mar	DISC
@	250MG	N18934 001	Jun 29, 1984	Mar	DISC
@	500MG	N18934 002	Jun 29, 1984	Mar	DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AB	SANDOZ	40MG/ML	N40719 001	Jan 29, 2009	Jan	NEWA
AB		40MG/ML	N40794 001	Mar 05, 2009	Feb	NEWA
AB		80MG/ML	N40719 002	Jan 29, 2009	Jan	NEWA
AB		80MG/ML	N40794 002	Mar 05, 2009	Feb	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	VISTAPHARM	EQ 5MG BASE/5ML	N75051 001	Jan 26, 2001	Mar	CMFD
----	------------	-----------------	------------	--------------	-----	------

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ SANDOZ	EQ 5MG BASE	N74478 001	Oct 05, 1995	Mar	DISC
@	EQ 10MG BASE	N72215 001	Jan 30, 1990	Mar	DISC

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

@ SOLCO HLTHCARE	50MG	N74453 001	Apr 27, 1995	Jan	CAHN
@	100MG	N74453 002	Apr 27, 1995	Jan	CAHN

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

AB	ALEMBIC LTD	250MG	N79067 001	Mar 13, 2009	Mar	NEWA
AB		500MG	N79067 002	Mar 13, 2009	Mar	NEWA
	@ SANDOZ	250MG	N18740 001	Oct 22, 1982	Mar	DISC
	@	500MG	N18740 002	Oct 22, 1982	Mar	DISC

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

	@ SANDOZ	150MG	N74450 001	May 16, 1996	Mar	DISC
	@	200MG	N74450 002	May 16, 1996	Mar	DISC
	@	250MG	N74450 003	May 16, 1996	Mar	DISC

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+	STIEFEL LABS INC	0.25%;81.35%;15%	N21026 001	Feb 16, 2006	Jan	CAHN
---	------------------	------------------	------------	--------------	-----	------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

	CYPRESS BIOSCIENCE	12.5MG	N22256 001	Jan 14, 2009	Jan	NEWA
		25MG	N22256 002	Jan 14, 2009	Jan	NEWA
		50MG	N22256 003	Jan 14, 2009	Jan	NEWA
+		100MG	N22256 004	Jan 14, 2009	Jan	NEWA

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	BARR	EQ 45MG BASE	N65485 001	Mar 17, 2009	Mar	NEWA
AB		EQ 90MG BASE	N65485 002	Mar 17, 2009	Mar	NEWA
AB		EQ 135MG BASE	N65485 003	Mar 17, 2009	Mar	NEWA
AB	IMPAX LABS INC	EQ 45MG BASE	N90024 001	Feb 03, 2009	Jan	NEWA
AB		EQ 90MG BASE	N90024 002	Feb 03, 2009	Jan	NEWA
AB		EQ 135MG BASE	N90024 003	Feb 03, 2009	Jan	NEWA
	SOLODYN					
AB	MEDICIS	EQ 45MG BASE	N50808 001	May 08, 2006	Jan	CFTG
AB		EQ 90MG BASE	N50808 002	May 08, 2006	Jan	CFTG
AB	+	EQ 135MG BASE	N50808 003	May 08, 2006	Jan	CFTG

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	GENERAMEDIX	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N78980 001	Apr 13, 2009	Mar	NEWA
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N78980 002	Apr 13, 2009	Mar	NEWA

>A> MIVACURIUM CHLORIDE

>A> INJECTABLE; INJECTION

>A> MIVACURIUM CHLORIDE

>A>	+	EBEWE PARENTA	EQ 2MG BASE/ML	N78562 001	Apr 30, 2009	Apr	NEWA
-----	---	---------------	----------------	------------	--------------	-----	------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

+	ACTAVIS ELIZABETH	10MG	N20616 008	Apr 20, 2007	Feb	CRLD
+		80MG	N20616 006	Oct 27, 2006	Feb	CRLD

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

>D>	AB	AB GENERICS	15MG	N74862 001	Jul 07, 1998	Apr	DISC
>A>		@	15MG	N74862 001	Jul 07, 1998	Apr	DISC
>D>	AB		30MG	N74862 002	Jul 07, 1998	Apr	DISC
>A>		@	30MG	N74862 002	Jul 07, 1998	Apr	DISC
>D>	AB		60MG	N74862 003	Jul 07, 1998	Apr	DISC
>A>		@	60MG	N74862 003	Jul 07, 1998	Apr	DISC
>D>	AB		100MG	N74769 001	Jul 02, 1998	Apr	DISC
>A>		@	100MG	N74769 001	Jul 02, 1998	Apr	DISC
>D>	AB		200MG	N74769 002	Jul 02, 1998	Apr	DISC
>A>		@	200MG	N74769 002	Jul 02, 1998	Apr	DISC

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

>A>	AB	ACCORD HLTHCARE INC	250MG	N90253 001	May 04, 2009	Apr	NEWA
>A>	AB	APOTEX CORP	250MG	N90419 001	Apr 22, 2009	Apr	NEWA
>A>	AB	MYLAN	250MG	N65520 001	May 04, 2009	Apr	NEWA
>A>	AB	TEVA PHARMS	250MG	N65491 001	May 06, 2009	Apr	NEWA
>A>	AB	ZYDUS PHARMS USA INC	250MG	N65433 001	May 04, 2009	Apr	NEWA

TABLET; ORAL

MYCOPHENOLATE MOFETIL

>A>	AB	ACCORD HLTHCARE	500MG	N65416 001	May 04, 2009	Apr	NEWA
>A>	AB	APOTEX	500MG	N90499 001	Apr 22, 2009	Apr	NEWA
>A>	AB	MYLAN	500MG	N65521 001	May 04, 2009	Apr	NEWA
>A>	AB	TEVA PHARMS	500MG	N65457 001	May 04, 2009	Apr	NEWA
>A>	AB	ZYDUS PHARMS USA INC	500MG	N65477 001	May 04, 2009	Apr	NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

AB		ACTAVIS ELIZABETH	500MG	N79093 001	Feb 27, 2009	Feb	NEWA
AB			750MG	N79093 002	Feb 27, 2009	Feb	NEWA
		@ SANDOZ	500MG	N75590 001	Feb 25, 2002	Mar	DISC
		@	750MG	N75590 002	Feb 25, 2002	Mar	DISC

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

+	STAT TRADE	EQ 375MG BASE	N20353 001	Jan 05, 1996	Mar	CTEC
+		EQ 500MG BASE	N20353 002	Jan 05, 1996	Mar	CTEC

NAPROXEN SODIUM

@	WATSON LABS FLORIDA	EQ 375MG BASE	N75416 002	Apr 23, 2003	Mar	DISC
@		EQ 500MG BASE	N75416 001	Aug 27, 2002	Mar	DISC

NIFEDIPINE

CAPSULE; ORAL

PROCARDIA

>D>	AB	PFIZER	10MG	N18482 001		Apr	CRLD
-----	----	--------	------	------------	--	-----	------

CAPSULE; ORALPROCARDIA

>A>	AB	+	PFIZER	10MG	N18482 001		Apr	CRLD
>D>	AB	+		20MG	N18482 002	Jul 24, 1986	Apr	DISC
>A>			@	20MG	N18482 002	Jul 24, 1986	Apr	DISC

NIMODIPINECAPSULE; ORALNIMODIPINE

AB	+	BARR		30MG	N77811 001	May 02, 2007	Mar	CRLD
			@ BAYER PHARMS	30MG	N18869 001	Dec 28, 1988	Feb	DISC

NITISINONECAPSULE; ORALORFADINRARE DIS

				2MG	N21232 001	Jan 18, 2002	Mar	CAHN
				5MG	N21232 002	Jan 18, 2002	Mar	CAHN
	+			10MG	N21232 003	Jan 18, 2002	Mar	CAHN

NITROFURANTOIN, MACROCRYSTALLINECAPSULE; ORALNITROFURANTOIN@ SANDOZ@@

			@ SANDOZ	25MG	N74336 001	Jan 25, 1995	Mar	DISC
			@	50MG	N74336 002	Jan 25, 1995	Mar	DISC
			@	100MG	N74336 003	Jan 25, 1995	Mar	DISC

OFLOXACINSOLUTION/DROPS; OPHTHALMICOFLOXACIN

AT			FDC LTD	0.3%	N78559 001	Feb 25, 2009	Feb	NEWA
----	--	--	---------	------	------------	--------------	-----	------

TABLET; ORALFLOXIN@ ORTHO MCNEIL JANSSEN@@

			@ ORTHO MCNEIL JANSSEN	200MG	N19735 001	Dec 28, 1990	Mar	DISC
			@	300MG	N19735 002	Dec 28, 1990	Mar	DISC
			@	400MG	N19735 003	Dec 28, 1990	Mar	DISC

OLSALAZINE SODIUMCAPSULE; ORALDIPENTUM

>A>	+	ALAVEN PHARM		250MG	N19715 001	Jul 31, 1990	Apr	CAHN
>D>	+	UCB INC		250MG	N19715 001	Jul 31, 1990	Apr	CAHN

OMEPRAZOLECAPSULE, DELAYED REL PELLETS; ORALOMEPRAZOLE

AB			DR REDDYS LABS	40MG	N78490 001	Apr 17, 2009	Mar	NEWA
AB			DR REDDYS LABS LTD	10MG	N78693 001	Mar 16, 2009	Mar	NEWA
AB				20MG	N78693 002	Mar 16, 2009	Mar	NEWA
AB			KREMERS URBAN DEV	40MG	N75410 003	Jan 23, 2009	Jan	NEWA

ONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTIONONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

AP			BEDFORD LABS	EQ 0.64MG BASE/ML	N78291 001	Apr 13, 2009	Mar	NEWA
----	--	--	--------------	-------------------	------------	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

>D>	MARSAM PHARMS LLC	EQ 250MG BASE/VIAL	N62856 001	Oct 26, 1988	Apr	DISC
>D>		EQ 500MG BASE/VIAL	N62856 002	Oct 26, 1988	Apr	DISC
>D>	AP	EQ 1GM BASE/VIAL	N62856 003	Oct 26, 1988	Apr	DISC
>D>	AP	EQ 2GM BASE/VIAL	N62856 004	Oct 26, 1988	Apr	DISC
>D>		EQ 4GM BASE/VIAL	N62856 005	Oct 26, 1988	Apr	DISC
>A>	@ WATSON LABS	EQ 250MG BASE/VIAL	N62856 001	Oct 26, 1988	Apr	DISC
>A>	@	EQ 500MG BASE/VIAL	N62856 002	Oct 26, 1988	Apr	DISC
>A>	@	EQ 1GM BASE/VIAL	N62856 003	Oct 26, 1988	Apr	DISC
>A>	@	EQ 2GM BASE/VIAL	N62856 004	Oct 26, 1988	Apr	DISC
>A>	@	EQ 4GM BASE/VIAL	N62856 005	Oct 26, 1988	Apr	DISC

OXAPROZIN

TABLET; ORAL

OXAPROZIN

@ SANDOZ

600MG

N75850 001 Apr 27, 2001 Mar DISC

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

+ WATSON LABS

10%(100MG/PACKET)

N22204 001 Jan 27, 2009 Mar CTNA

OXYBUTYNIN CHLORIDE

+ WATSON LABS

10%(100MG/PACKET)

N22204 001 Jan 27, 2009 Jan NEWA

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB OSMOTICA PHARM

5MG

N78503 001 Feb 04, 2009 Jan NEWA

AB

10MG

N78503 002 Feb 04, 2009 Jan NEWA

AB

15MG

N78503 003 Feb 04, 2009 Jan NEWA

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB SUN PHARM INDS INC

5MG

N90659 001 Apr 10, 2009 Mar NEWA

AB

15MG

N90659 002 Apr 10, 2009 Mar NEWA

AB

30MG

N90659 003 Apr 10, 2009 Mar NEWA

AB VINTAGE PHARMS

5MG

N77712 003 Mar 02, 2009 Mar NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP GENERAMEDIX

30MG/VIAL

N78300 001 Mar 10, 2009 Feb NEWA

AP

90MG/VIAL

N78300 002 Mar 10, 2009 Feb NEWA

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE; ORAL

CREON

>A>

>A> SOLVAY

30,000USP UNITS;6,000USP UNITS;19,000USP UNITS

N20725 001 Apr 30, 2009 Apr NEWA

>A>

60,000USP UNITS;12,000USP UNITS;38,000USP UNITS

N20725 002 Apr 30, 2009 Apr NEWA

>A> +

120,000USP UNITS;24,000USP UNITS;76,000USP UNITS

N20725 003 Apr 30, 2009 Apr NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

>D>	AP	HOSPIRA	2MG/ML	N72321 001	Jan 19, 1989	Apr	DISC
>A>		@	2MG/ML	N72321 001	Jan 19, 1989	Apr	DISC

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB		KUDCO IRELAND	EQ 20MG BASE	N78281 001	Mar 17, 2009	Mar	NEWA
AB			EQ 40MG BASE	N78281 002	Mar 17, 2009	Mar	NEWA

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN-VK

>D>	AA	TEVA	EQ 250MG BASE/5ML	N60456 002		Apr	CRLD
>A>	AA	+	EQ 250MG BASE/5ML	N60456 002		Apr	CRLD
		VEETIDS					
		@ APOTHECON	EQ 125MG BASE/5ML	N61410 001		Mar	DISC
		@	EQ 250MG BASE/5ML	N61410 002		Mar	DISC

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

>D>	AB	MORTON GROVE	125MG/5ML	N40420 001	Apr 19, 2002	Apr	CAHN
>A>	AB	WOCKHARDT EU	125MG/5ML	N40420 001	Apr 19, 2002	Apr	CAHN

PHENYTOIN SODIUM

CAPSULE; ORAL

PROMPT PHENYTOIN SODIUM

		@ IVAX PHARMS	100MG PROMPT	N80259 001		Jan	DISC
--	--	---------------	--------------	------------	--	-----	------

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

>A>	AB	LANNETT	7.5MG	N77220 002	May 06, 2009	Apr	NEWA
-----	----	---------	-------	------------	--------------	-----	------

PINDOLOL

TABLET; ORAL

PINDOLOL

		@ SANDOZ	5MG	N73608 001	Mar 29, 1993	Mar	DISC
		@	10MG	N73609 001	Mar 29, 1993	Mar	DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

AA		GAVIS PHARMS	17GM/SCOOPFUL	N77736 001	May 26, 2006	Jan	CAHN
		@ TEVA PHARMS	17GM/SCOOPFUL	N77445 001	May 04, 2006	Jan	DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

GOLYTELY

+		BRAINTREE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	N19011 001	Jul 13, 1984	Mar	CTEC
---	--	-----------	--	------------	--------------	-----	------

FOR SUSPENSION; ORAL

CO-LAV

@ BOCA PHARMA 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 N73428 001 Jan 28, 1992 Mar DISC
.84GM/BOT;22.72GM/BOT

GO-EVAC

@ BOCA PHARMA 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 N73433 001 Apr 28, 1992 Mar DISC
.86GM/BOT;22.74GM/BOT

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

@ KV PHARM 8MEQ N18238 001 Feb DISC

MICRO-K 10

@ KV PHARM 10MEQ N18238 002 May 14, 1984 Feb DISC

POTASSIUM CHLORIDE

@ KV PHARM 10MEQ N70980 001 Feb 17, 1987 Feb DISC

WATSON LABS FLORIDA

8MEQ N77419 001 Jun 02, 2008 Feb CTEC

+

10MEQ N77419 002 Jun 02, 2008 Feb CRLD

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

>D> + HOSPIRA 1.5MEQ/ML N83345 001 Apr DISC

>A> @ 1.5MEQ/ML N83345 001 Apr DISC

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB + WATSON LABS FLORIDA 10MEQ N75604 001 Apr 10, 2002 Jan CRLD

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

@ SANDOZ EQ 1MG BASE N72576 001 May 16, 1989 Mar DISC

@ EQ 2MG BASE N72577 001 May 16, 1989 Mar DISC

@ EQ 5MG BASE N72578 001 May 16, 1989 Mar DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA AMNEAL PHARMS EQ 15MG BASE/5ML N78345 001 Mar 10, 2009 Feb NEWA

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

>D> + BAUSCH AND LOMB EQ 0.11% PHOSPHATE N40065 001 Jul 29, 1994 Apr DISC

>A> @ EQ 0.11% PHOSPHATE N40065 001 Jul 29, 1994 Apr DISC

PREDNISON

TABLET; ORAL

PREDNISON

@ SANDOZ 10MG N89983 001 Jan 12, 1989 Mar DISC

@ 50MG N89984 001 Jan 12, 1989 Mar DISC

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN

>D> + DENTSPLY PHARM 4% N21382 001 Apr CTNA

>A> CITANEST PLAIN DENTAL

>A> + DENTSPLY PHARM 4% N21382 001 Apr CTNA

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA	SUN PHARM INDS INC	6.25MG/5ML	N40891 001	Mar 13, 2009	Mar	NEWA
----	--------------------	------------	------------	--------------	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DOLENE

AA	HERITAGE PHARMS INC	65MG	N80530 001		Mar	CMFD
----	---------------------	------	------------	--	-----	------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	UPSHER SMITH	60MG	N78311 001	Mar 06, 2009	Feb	NEWA
AB		80MG	N78311 002	Mar 06, 2009	Feb	NEWA
AB		120MG	N78311 003	Mar 06, 2009	Feb	NEWA
AB		160MG	N78311 004	Mar 06, 2009	Feb	NEWA

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

@ SANDOZ

10MG

N70663 001 Jun 13, 1986 Mar DISC

@

20MG

N70664 001 Jun 13, 1986 Mar DISC

@

40MG

N70665 001 Jun 13, 1986 Mar DISC

@

60MG

N70666 001 Oct 10, 1986 Mar DISC

@

80MG

N70667 001 Jun 13, 1986 Mar DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

CORPHED

@ SANDOZ

60MG;2.5MG

N88602 001 Apr 11, 1985 Mar DISC

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

+ SANDOZ

60MG;2.5MG

N88193 001 May 17, 1983 Mar CTEC

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

AB	RANBAXY	5MG	N78849 001	Mar 06, 2009	Feb	NEWA
AB		10MG	N78849 002	Mar 06, 2009	Feb	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

>D>	AP	BEDFORD	EQ 25MG BASE/ML	N74764 001	Nov 19, 2004	Apr	DISC
>A>		@	EQ 25MG BASE/ML	N74764 001	Nov 19, 2004	Apr	DISC

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 15MG BASE/ML	N78312 001	Sep 02, 2008	Feb	CTNA
AA	WOCKHARDT	EQ 15MG BASE/ML	N79212 001	Feb 23, 2009	Feb	NEWA

RISPERIDONE

SOLUTION; ORAL

RISPERDAL

AA	+ ORTHO MCNEIL JANSSEN	1MG/ML	N20588 001	Jun 10, 1996	Jan	CFTG
AA	TEVA	1MG/ML	N76440 001	Jan 30, 2009	Jan	NEWA

TABLET; ORAL

RISPERIDONE

AB	CADISTA PHARMS	0.25MG	N78828 001	Mar 23, 2009	Mar	NEWA
AB		0.5MG	N78828 002	Mar 23, 2009	Mar	NEWA
AB		1MG	N78828 003	Mar 23, 2009	Mar	NEWA
AB		2MG	N78828 004	Mar 23, 2009	Mar	NEWA
AB		3MG	N78828 005	Mar 23, 2009	Mar	NEWA
AB		4MG	N78828 006	Mar 23, 2009	Mar	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

AB	ORTHO MCNEIL JANSSEN	0.5MG	N21444 001	Apr 02, 2003	Feb	CFTG
AB		2MG	N21444 003	Apr 02, 2003	Feb	CFTG
>D>		3MG	N21444 004	Dec 23, 2004	Apr	CFTG
>A>	AB	3MG	N21444 004	Dec 23, 2004	Apr	CFTG
>D>		4MG	N21444 005	Dec 23, 2004	Apr	CFTG
>A>	AB	4MG	N21444 005	Dec 23, 2004	Apr	CFTG

RISPERIDONE

AB	DR REDDYS LABS LTD	0.5MG	N77328 001	Feb 24, 2009	Feb	NEWA
AB		2MG	N77328 003	Feb 24, 2009	Feb	NEWA
>A>	KALI LABS	0.25MG	N77494 001	Apr 30, 2009	Apr	NEWA
>A>	AB	0.5MG	N77494 002	Apr 30, 2009	Apr	NEWA
>A>	AB	2MG	N77494 004	Apr 30, 2009	Apr	NEWA
>A>	AB	3MG	N77494 005	Apr 30, 2009	Apr	NEWA
>A>	AB	4MG	N77494 006	Apr 30, 2009	Apr	NEWA
>A>	ZYDUS PHARMS USA	0.5MG	N78516 001	May 01, 2009	Apr	NEWA
>A>	AB	2MG	N78516 003	May 01, 2009	Apr	NEWA

>D> RITODRINE HYDROCHLORIDE

>D> INJECTABLE; INJECTION

>D> RITODRINE HYDROCHLORIDE

>D>	+	HOSPIRA	10MG/ML	N71618 001	Feb 28, 1991	Apr	DISC
>A>		@	10MG/ML	N71618 001	Feb 28, 1991	Apr	DISC
>D>	+		15MG/ML	N71619 001	Feb 28, 1991	Apr	DISC
>A>		@	15MG/ML	N71619 001	Feb 28, 1991	Apr	DISC
>D>		RITODRINE HYDROCHLORIDE	IN DEXTROSE 5% IN PLASTIC CONTAINER				
>D>	+	HOSPIRA	30MG/100ML	N71438 001	Jan 22, 1991	Apr	DISC
>A>		@	30MG/100ML	N71438 001	Jan 22, 1991	Apr	DISC

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

>A>	AB	HUAHAI US INC	EQ 0.25MG BASE	N78110 001	May 05, 2008	Apr	CAHN
>A>	AB		EQ 0.5MG BASE	N78110 002	May 05, 2008	Apr	CAHN
>A>	AB		EQ 1MG BASE	N78110 003	May 05, 2008	Apr	CAHN
>A>	AB		EQ 2MG BASE	N78110 004	May 05, 2008	Apr	CAHN
>A>	AB		EQ 3MG BASE	N78110 005	May 05, 2008	Apr	CAHN
>A>	AB		EQ 4MG BASE	N78110 006	May 05, 2008	Apr	CAHN
>D>	AB	PAR PHARM	EQ 0.25MG BASE	N78110 001	May 05, 2008	Apr	CAHN
>D>	AB		EQ 0.5MG BASE	N78110 002	May 05, 2008	Apr	CAHN
>D>	AB		EQ 1MG BASE	N78110 003	May 05, 2008	Apr	CAHN
>D>	AB		EQ 2MG BASE	N78110 004	May 05, 2008	Apr	CAHN
>D>	AB		EQ 3MG BASE	N78110 005	May 05, 2008	Apr	CAHN
>D>	AB		EQ 4MG BASE	N78110 006	May 05, 2008	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

>A>		SMITHKLINE BEECHAM	EQ 6MG BASE	N22008 006	Apr 10, 2009	Apr	NEWA
-----	--	--------------------	-------------	------------	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

>D>	AB	ENDO PHARMS	5MG	N74565 001	Aug 02, 1996	Apr	DISC
>A>		@	5MG	N74565 001	Aug 02, 1996	Apr	DISC
>D>	AB	SIEGFRIED	5MG	N74672 001	Apr 01, 1997	Apr	DISC
>A>		@	5MG	N74672 001	Apr 01, 1997	Apr	DISC

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB		AUSTARPHARMA LLC	EQ 25MG BASE	N78677 001	Mar 04, 2009	Feb	NEWA
AB			EQ 50MG BASE	N78677 002	Mar 04, 2009	Feb	NEWA
AB			EQ 100MG BASE	N78677 003	Mar 04, 2009	Feb	NEWA

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB		LUPIN	5MG	N78103 005	Apr 14, 2009	Mar	NEWA
----	--	-------	-----	------------	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATE

AA		KVK TECH	454GM/BOT	N40905 001	Mar 30, 2009	Mar	NEWA
----	--	----------	-----------	------------	--------------	-----	------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN NORDIFLEX

NOVO NORDISK INC

30MG/3ML

N21148 007	Mar 10, 2009	Mar	NEWA
------------	--------------	-----	------

STANZOLOL

TABLET; ORAL

WINSTROL

@ LUNDBECK INC

2MG

N12885 001	May 14, 1984	Mar	CAHN
------------	--------------	-----	------

STAVUDINE

FOR SOLUTION; ORAL

STAVUDINE

CIPLA LTD

1MG/ML

N78030 001	Mar 20, 2009	Mar	NEWA
------------	--------------	-----	------

SUCCIMER

CAPSULE; ORAL

CHEMET

+ LUNDBECK INC

100MG

N19998 002	Jan 30, 1991	Mar	CAHN
------------	--------------	-----	------

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB		PERRIGO CO TENNESSEE	10%	N78649 001	Mar 23, 2009	Mar	NEWA
----	--	----------------------	-----	------------	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

>D> SULF-10

>D>	AT	NOVARTIS	10%	N80025 001		Apr	DISC
-----	----	----------	-----	------------	--	-----	------

>A>		@	10%	N80025 001		Apr	DISC
-----	--	---	-----	------------	--	-----	------

SULFACETAMIDE SODIUM

>D>		+ ALCON	30%	N89068 001	May 05, 1987	Apr	DISC
-----	--	---------	-----	------------	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM

>A>	@ ALCON	30%	N89068 001	May 05, 1987	Apr	DISC
-----	---------	-----	------------	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOPRIM

AB	PAR PHARM	400MG;80MG	N70022 001	Feb 15, 1985	Mar	CMFD
----	-----------	------------	------------	--------------	-----	------

SULFAMETHOPRIM-DS

AB	PAR PHARM	800MG;160MG	N70032 001	Feb 15, 1985	Mar	CMFD
----	-----------	-------------	------------	--------------	-----	------

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ SANDOZ	800MG;160MG	N70890 001	Nov 13, 1986	Mar	DISC
----------	-------------	------------	--------------	-----	------

SULINDAC

TABLET; ORAL

SULINDAC

@ SANDOZ	150MG	N72712 001	Aug 30, 1991	Mar	DISC
----------	-------	------------	--------------	-----	------

@	200MG	N72713 001	Aug 30, 1991	Mar	DISC
---	-------	------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX

AP	+ GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N20080 001	Dec 28, 1992	Jan	CFTG
----	-------------------	--	------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AP	APP PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N79242 001	Mar 02, 2009	Feb	NEWA
----	------------	--	------------	--------------	-----	------

AP	BEDFORD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N79123 001	Feb 06, 2009	Jan	NEWA
----	---------	--	------------	--------------	-----	------

AP	SANDOZ	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N78067 002	Feb 06, 2009	Jan	NEWA
----	--------	---------------------------------------	------------	--------------	-----	------

AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78067 001	Feb 06, 2009	Jan	NEWA
----	--	--	------------	--------------	-----	------

AP	TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N78318 001	Feb 06, 2009	Jan	NEWA
----	-----------------	---------------------------------------	------------	--------------	-----	------

AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78318 002	Feb 06, 2009	Jan	NEWA
----	--	--	------------	--------------	-----	------

AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N77907 001	Feb 06, 2009	Jan	NEWA
----	--	--	------------	--------------	-----	------

AP	WOCKHARDT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78593 001	Feb 06, 2009	Jan	NEWA
----	-----------	--	------------	--------------	-----	------

TABLET; ORAL

IMITREX

AB	GLAXOSMITHKLINE	EQ 25MG BASE	N20132 002	Jun 01, 1995	Jan	CFTG
----	-----------------	--------------	------------	--------------	-----	------

AB		EQ 50MG BASE	N20132 003	Jun 01, 1995	Jan	CFTG
----	--	--------------	------------	--------------	-----	------

AB	+	EQ 100MG BASE	N20132 001	Jun 01, 1995	Jan	CFTG
----	---	---------------	------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AB	RANBAXY	EQ 100MG BASE	N76572 001	Feb 09, 2009	Jan	NEWA
----	---------	---------------	------------	--------------	-----	------

AB	TEVA	EQ 25MG BASE	N76840 001	Feb 09, 2009	Jan	NEWA
----	------	--------------	------------	--------------	-----	------

AB		EQ 50MG BASE	N76840 002	Feb 09, 2009	Jan	NEWA
----	--	--------------	------------	--------------	-----	------

AB		EQ 100MG BASE	N76840 003	Feb 09, 2009	Jan	NEWA
----	--	---------------	------------	--------------	-----	------

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

CPPI CV	EQ 37.5MG BASE	N21938 004	Mar 31, 2009	Mar	NEWA
---------	----------------	------------	--------------	-----	------

TAMOXIFEN CITRATE

TABLET; ORAL

TAMOXIFEN CITRATE

@	ROXANE	EQ 10MG BASE	N76027 001	Feb 20, 2003	Mar	DISC
@		EQ 20MG BASE	N76027 002	Feb 20, 2003	Mar	DISC

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION

NEUROLITE

>D>		LANTHEUS MEDCL	N/A/VIAL	N20256 001	Nov 23, 1994	Apr	CPOT
>A>			N/A	N20256 001	Nov 23, 1994	Apr	CPOT

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

>D>	AP	+	DRAXIMAGE	N/A	N18035 001		Apr	CTEC
>A>		+		N/A	N18035 001		Apr	CTEC
>D>			DRAXIMAGE MDP-25					
>D>	AP	+	DRAXIMAGE	N/A	N18035 002	Feb 27, 2004	Apr	DISC
>A>		@		N/A	N18035 002	Feb 27, 2004	Apr	DISC
>D>			TECHNETIUM TC 99M MPI MDP					
>D>	AP		GE HEALTHCARE	N/A	N18141 001		Apr	DISC
>A>		@		N/A	N18141 001		Apr	DISC
>A>		@		N/A	N18141 002	Jun 12, 1989	Apr	DISC

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M SESTAMIBI

>A>	AP		CARDINAL HEALTH 414	N/A	N78809 001	Apr 28, 2009	Apr	NEWA
>A>	AP		DRAXIMAGE	N/A	N78806 001	Apr 29, 2009	Apr	NEWA

TELBIVUDINE

>A>			SOLUTION; ORAL					
>A>			TYZEKA					
>A>		+	NOVARTIS	100MG/5ML	N22154 001	Apr 28, 2009	Apr	NEWA

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

@	NOVEL LABS INC	30MG	N71457 001	Apr 21, 1987	Mar	CAHN
---	----------------	------	------------	--------------	-----	------

TEMOZOLOMIDE

POWDER; INTRAVENOUS

TEMODAR

+	SCHERING	100MG/VIAL	N22277 001	Feb 27, 2009	Feb	NEWA
---	----------	------------	------------	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

HYTRIN

	ABBOTT	EQ 1MG BASE	N19057 001	Aug 07, 1987	Mar	CTEC
+		EQ 2MG BASE	N19057 002	Aug 07, 1987	Mar	CTEC
		EQ 5MG BASE	N19057 003	Aug 07, 1987	Mar	CTEC
		EQ 10MG BASE	N19057 004	Aug 07, 1987	Mar	CTEC
		TERAZOSIN HYDROCHLORIDE				
@	SANDOZ	EQ 1MG BASE	N74315 001	Dec 31, 1998	Mar	DISC

TABLET; ORAL

TERAZOSIN HYDROCHLORIDE

@ SANDOZ	EQ 2MG BASE	N74315 002	Dec 31, 1998	Mar	DISC
@	EQ 5MG BASE	N74315 003	Dec 31, 1998	Mar	DISC
@	EQ 10MG BASE	N74315 004	Dec 31, 1998	Mar	DISC

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

LILLY	0.6MG/2.4ML (0.25MG/ML)	N21318 002	Jun 25, 2008	Feb	NEWA
+	0.75MG/3ML (0.25MG/ML)	N21318 001	Nov 26, 2002	Feb	CPOT

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

BX	+	UNIMED PHARMS	1% (5GM/PACKET)	N21015 002	Feb 28, 2000	Mar	CTEC
			1% (2.5GM/PACKET)	N21015 001	Feb 28, 2000	Mar	CTEC
		TESTOSTERONE					
		@ WATSON LABS	1% (2.5GM/PACKET)	N76737 001	Jan 27, 2006	Mar	DISC
		@	1% (5GM/PACKET)	N76737 002	Jan 27, 2006	Mar	DISC

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

>A>		@ ENDO PHARM	200MG/ML	N09165 001		Apr	CAHN	
>A>	AO	+	200MG/ML	N09165 003		Apr	CAHN	
>D>	AO	+	ENDO PHARMS	200MG/ML	N09165 003		Apr	CAHN
>D>		@	200MG/ML	N09165 001		Apr	CAHN	
		@	200MG/ML	N09165 001		Mar	CAHN	
AO	+		200MG/ML	N09165 003		Mar	CAHN	

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

>D>	+	KENWOOD LABS	0.05%	N86576 002		Apr	CAHN
>D>			0.1%	N86576 001		Apr	CAHN
>A>	+	NYCOMED US	0.05%	N86576 002		Apr	CAHN
>A>			0.1%	N86576 001		Apr	CAHN

SPRAY; NASAL

TYZINE

>D>	+	KENWOOD LABS	0.1%	N86576 003		Apr	CAHN
>A>	+	NYCOMED US	0.1%	N86576 003		Apr	CAHN

THEOPHYLLINE

ELIXIR; ORAL

THEOPHYLLINE

>D>	AA	ACTAVIS MID ATLANTIC	80MG/15ML	N85863 001		Apr	CAHN
>A>	AA	PRECISION DOSE	80MG/15ML	N85863 001		Apr	CAHN

SOLUTION; ORAL

THEOPHYLLINE

		@ ROXANE	80MG/15ML	N87449 001	Sep 15, 1983	Mar	DISC
--	--	----------	-----------	------------	--------------	-----	------

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOPTIC

AT	+	ATON	EQ 0.25% BASE	N18086 001		Feb	CAHN
----	---	------	---------------	------------	--	-----	------

SOLUTION/DROPS; OPHTHALMIC									
TIMOPTIC									
AT	+	ATON	EQ 0.5% BASE		N18086 002			Feb	CAHN
TIMOPTIC IN OCUDOSE									
	+	ATON	EQ 0.25% BASE		N19463 001	Nov 05, 1986		Feb	CAHN
	+		EQ 0.5% BASE		N19463 002	Nov 05, 1986		Feb	CAHN
SOLUTION, GEL FORMING/DROPS; OPHTHALMIC									
TIMOPTIC-XE									
AB	+	ATON	EQ 0.25% BASE		N20330 001	Nov 04, 1993		Feb	CAHN
AB	+		EQ 0.5% BASE		N20330 002	Nov 04, 1993		Feb	CAHN
TABLET; ORAL									
TIMOLOL MALEATE									
		MYLAN	5MG		N72666 001	Jun 08, 1990		Mar	CTEC
			10MG		N72667 001	Jun 08, 1990		Mar	CTEC
	+		20MG		N72668 001	Jun 08, 1990		Mar	CTEC
		@ SANDOZ	5MG		N72550 001	Apr 13, 1989		Mar	DISC
		@	10MG		N72551 001	Apr 13, 1989		Mar	DISC
		@	20MG		N72552 001	Apr 13, 1989		Mar	DISC
<u>TOLAZAMIDE</u>									
TABLET; ORAL									
TOLAZAMIDE									
		IVAX PHARMS	100MG		N18894 001	Nov 02, 1984		Mar	CTEC
		@ SANDOZ	100MG		N71633 001	Dec 09, 1987		Mar	DISC
		@	250MG		N70289 001	Mar 13, 1986		Mar	DISC
		@	500MG		N70290 001	Mar 13, 1986		Mar	DISC
<u>TOLBUTAMIDE</u>									
TABLET; ORAL									
TOLBUTAMIDE									
		@ SANDOZ	500MG		N86574 001			Mar	DISC
<u>TOLMETIN SODIUM</u>									
TABLET; ORAL									
TOLMETIN SODIUM									
		@ SANDOZ	EQ 200MG BASE		N73588 001	Jul 31, 1992		Mar	DISC
		@	EQ 600MG BASE		N74002 001	Sep 27, 1993		Mar	DISC
<u>TOPIRAMATE</u>									
CAPSULE; ORAL									
TOPAMAX									
AB		ORTHO MCNEIL JANSSEN	15MG		N20844 001	Oct 26, 1998		Mar	CFTG
AB	+		25MG		N20844 002	Oct 26, 1998		Mar	CFTG
TOPIRAMATE									
AB		BARR	15MG		N76448 001	Apr 15, 2009		Mar	NEWA
AB			25MG		N76448 002	Apr 15, 2009		Mar	NEWA
AB		COBALT LABS INC	15MG		N77868 001	Apr 15, 2009		Mar	NEWA
AB			25MG		N77868 002	Apr 15, 2009		Mar	NEWA
AB		TEVA	15MG		N76575 001	Apr 17, 2009		Mar	NEWA
AB			25MG		N76575 002	Apr 17, 2009		Mar	NEWA
TABLET; ORAL									
TOPAMAX									
AB	+	ORTHO MCNEIL JANSSEN	25MG		N20505 004	Dec 24, 1996		Mar	CFTG
AB			50MG		N20505 005	Dec 24, 1996		Mar	CFTG
AB			100MG		N20505 001	Dec 24, 1996		Mar	CFTG
AB			200MG		N20505 002	Dec 24, 1996		Mar	CFTG

TABLET; ORAL

TOPIRAMATE

AB	APOTEX INC	25MG	N77733 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77733 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77733 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77733 004	Mar 27, 2009	Mar	NEWA
AB	AUROBINDO PHARMA	25MG	N78462 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N78462 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N78462 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N78462 004	Mar 27, 2009	Mar	NEWA
AB	BARR	25MG	N76315 001	Mar 27, 2009	Mar	NEWA
AB		100MG	N76315 002	Mar 27, 2009	Mar	NEWA
AB		200MG	N76315 003	Mar 27, 2009	Mar	NEWA
AB	CIPLA LTD	25MG	N76343 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76343 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76343 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76343 004	Mar 27, 2009	Mar	NEWA
AB	COBALT LABS INC	25MG	N77643 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77643 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77643 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77643 004	Mar 27, 2009	Mar	NEWA
AB	GLENMARK GENERICS	25MG	N77627 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77627 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77627 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77627 004	Mar 27, 2009	Mar	NEWA
AB	INVAGEN PHARMS	25MG	N79162 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N79162 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N79162 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N79162 004	Mar 27, 2009	Mar	NEWA
AB	MYLAN	25MG	N76314 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76314 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76314 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76314 004	Mar 27, 2009	Mar	NEWA
AB	PAR PHARM	25MG	N76311 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76311 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76311 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76311 004	Mar 27, 2009	Mar	NEWA
AB	PLIVA HRVATSKA DOO	25MG	N77905 001	Mar 30, 2009	Mar	NEWA
AB		50MG	N77905 002	Mar 30, 2009	Mar	NEWA
AB		100MG	N77905 003	Mar 30, 2009	Mar	NEWA
AB		200MG	N77905 004	Mar 30, 2009	Mar	NEWA
AB	RANBAXY	25MG	N76327 001	Mar 27, 2009	Mar	NEWA
AB		100MG	N76327 002	Mar 27, 2009	Mar	NEWA
AB		200MG	N76327 003	Mar 27, 2009	Mar	NEWA
AB	ROXANE	25MG	N76306 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76306 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76306 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76306 004	Mar 27, 2009	Mar	NEWA
AB	SUN PHARM INDS LTD	25MG	N90278 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N90278 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N90278 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N90278 004	Mar 27, 2009	Mar	NEWA
AB	TEVA	25MG	N76317 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76317 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76317 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76317 004	Mar 27, 2009	Mar	NEWA

TABLET; ORAL

TOPIRAMATE

AB	TORRENT PHARMS	25MG	N79153 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N79153 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N79153 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N79153 004	Mar 27, 2009	Mar	NEWA
AB	UNICHEM	25MG	N90162 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N90162 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N90162 003	Mar 27, 2009	Mar	NEWA
AB	ZYDUS PHARMS USA INC	25MG	N78235 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N78235 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N78235 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N78235 004	Mar 27, 2009	Mar	NEWA

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	HETERO DRUGS	5MG	N79234 001	Jan 27, 2009	Jan	NEWA
AB		10MG	N79234 002	Jan 27, 2009	Jan	NEWA
AB		20MG	N79234 003	Jan 27, 2009	Jan	NEWA
AB		100MG	N79234 004	Jan 27, 2009	Jan	NEWA

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

BC	+ PURDUE PHARMA	100MG	N21745 001	Dec 30, 2008	Mar	CAHN
BC		200MG	N21745 002	Dec 30, 2008	Mar	CAHN
BC		300MG	N21745 003	Dec 30, 2008	Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

TRAMADOL HYDROCHLORIDE

@ ETHYPHARM NORTH

50MG

N21693 001 May 05, 2005 Mar CAHN

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	ALVOGEN	50MG	N71636 001	Apr 18, 1988	Feb	CAHN
AB		100MG	N71514 001	Apr 18, 1988	Feb	CAHN
	@ SANDOZ	50MG	N72484 001	Apr 30, 1990	Mar	DISC
	@	100MG	N72483 001	Apr 30, 1990	Mar	DISC

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

>A>	+ ALLERGAN	60MG	N22103 001	Aug 03, 2007	Apr	CAHN
>D>	+ ENDO PHARMS	60MG	N22103 001	Aug 03, 2007	Apr	CAHN
	+	60MG	N22103 001	Aug 03, 2007	Mar	CAHN

TABLET; ORAL

SANCTURA

>A>	+ ALLERGAN	20MG	N21595 001	May 28, 2004	Apr	CAHN
>D>	+ ENDO PHARMS	20MG	N21595 001	May 28, 2004	Apr	CAHN
	+	20MG	N21595 001	May 28, 2004	Mar	CAHN

TRYPAN BLUE

SOLUTION; OPHTHALMIC

MEMBRANEBLUE

+ DORC

0.15%

N22278 001 Feb 20, 2009 Feb NEWA

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

>A>	+	ENDO PHARM	40MG/ML	N20892 001	Sep 25, 1998	Apr	CAHN
>D>	+	ENDO PHARMS	40MG/ML	N20892 001	Sep 25, 1998	Apr	CAHN
	+		40MG/ML	N20892 001	Sep 25, 1998	Mar	CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

>D>	+	ABRAXIS PHARM	EQ 10GM BASE/VIAL	N62663 004	Nov 28, 1997	Apr	CTEC
>A>	AP	+	EQ 10GM BASE/VIAL	N62663 004	Nov 28, 1997	Apr	CTEC
>A>	AP	HOSPIRA INC	EQ 10GM BASE/VIAL	N65455 001	Apr 29, 2009	Apr	NEWA

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

>D>	AP	BEDFORD	2.5MG/ML	N72888 001	Jul 28, 1995	Apr	DISC
>A>		@	2.5MG/ML	N72888 001	Jul 28, 1995	Apr	DISC

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

		@ SANDOZ	40MG	N73168 001	Jul 31, 1992	Mar	DISC
		@	80MG	N71423 001	May 24, 1988	Mar	DISC
		@	120MG	N71424 001	May 25, 1988	Mar	DISC

ZOLPIDEM TARTRATE

TABLET; SUBLINGUAL

EDLUAR

		OREXO AB	5MG	N21997 001	Mar 13, 2009	Mar	NEWA
	+		10MG	N21997 002	Mar 13, 2009	Mar	NEWA

OTC DRUG PRODUCT LIST - 29TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

2-1

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

OHM LABS 650MG N76200 001 Mar 19, 2002 Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD 5MG/5ML N90474 002 Mar 30, 2009 Mar NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

DR REDDYS LABS LTD 5MG/5ML N90474 001 Mar 30, 2009 Mar NEWA

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

ORCHID HLTHCARE 5MG N78862 001 Feb 19, 2009 Feb NEWA

10MG N78862 002 Feb 19, 2009 Feb NEWA

CETIRIZINE HYDROCHLORIDE HIVES

ORCHID HLTHCARE 5MG N78862 003 Feb 19, 2009 Feb NEWA

10MG N78862 004 Feb 19, 2009 Feb NEWA

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

>A> AVANTHI INC 12MG N40829 001 May 13, 2009 Apr NEWA

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

+ RECKITT BENCKISER EQ 30MG HBR/5ML N18658 001 Oct 08, 1982 Feb CAHN

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

BANNER PHARMACAPS EQ 200MG FREE ACID AND POTASSIUM N78682 001 Mar 24, 2009 Mar NEWA
SALT

MIDOL LIQUID GELS

+ BANNER PHARMACAPS 200MG N21472 001 Oct 18, 2002 Feb CTNA

TABLET; ORAL

IBUPROFEN

@ SANDOZ 200MG N70733 001 Sep 19, 1986 Mar DISC

>D> MEDIPREN

>D> MCNEIL 200MG N70475 001 Feb 06, 1986 Apr DISC

>A> @ 200MG N70475 001 Feb 06, 1986 Apr DISC

>D> 200MG N71215 001 Jun 26, 1986 Apr DISC

>A> @ 200MG N71215 001 Jun 26, 1986 Apr DISC

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

@ LILLY 50 UNITS/ML;50 UNITS/ML N20100 001 Apr 29, 1992 Jan DISC

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

IVAX PHARMS

EQ 2MG BASE

N76880 001 Feb 18, 2009 Feb NEWA

EQ 4MG BASE

N77850 001 Feb 18, 2009 Feb NEWA

POTASSIUM IODIDE

SOLUTION; ORAL

THYROSHIELD

>D>

FLEMING

65MG/ML

N77218 001 Jan 12, 2005 Apr CRLD

>A>

+

65MG/ML

N77218 001 Jan 12, 2005 Apr CRLD

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

@ SANDOZ

EQ 75MG BASE

N75519 001 Sep 26, 2002 Mar DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2009

NO APRIL 2009 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2009 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
022320 001	4717720	May 31, 2010	DS DP			
	RE34440	May 31, 2010			U-818	
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
020983 001	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 06, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 001					>A> PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 002					>A> PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 003					>A> PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 004					>A> PC	Jul 13, 2009
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
022325 001	5134127	Jan 23, 2010	DP			
	5376645	Jan 23, 2010	DP			
	6869939	May 04, 2022	DP			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 001	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 002	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 003	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 004	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 005	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 006	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 007	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 008	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 009	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 010	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 011	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 001	>A> 5399578	Mar 21, 2012	DS DP U-3		>A> NC	Apr 30, 2012
	>A> 5399578*PED	Sep 21, 2012				
	>A> 6294197	Jun 18, 2017	DP U-3			
	>A> 6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 002	>A> 5399578	Mar 21, 2012	DS DP U-3		>A> NC	Apr 30, 2012
	>A> 5399578*PED	Sep 21, 2012				
	>A> 6294197	Jun 18, 2017	DP U-3			
	>A> 6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 003	>A> 5399578	Mar 21, 2012	DS DP U-3		>A> NC	Apr 30, 2012
	>A> 5399578*PED	Sep 21, 2012				
	>A> 6294197	Jun 18, 2017	DP U-3			
	>A> 6294197*PED	Dec 18, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 004	>A> 5399578	Mar 21, 2012	DS DP U-3		>A> NC	Apr 30, 2012
	>A> 5399578*PED	Sep 21, 2012				
	>A> 6294197	Jun 18, 2017	DP U-3			
	>A> 6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 005	>A> 5399578	Mar 21, 2012	DS DP U-3		>A> NC	Apr 30, 2012
	>A> 5399578*PED	Sep 21, 2012				
	>A> 6294197	Jun 18, 2017	DP U-3			
	>A> 6294197*PED	Dec 18, 2017				
<u>AMMONIA, N-13 - AMMONIA N 13</u>						
022119 001					>A> NCE >A> W	Aug 23, 2012 Aug 23, 2012
<u>AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE - PREVPAC</u>						
050757 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5013743	Feb 12, 2010		U-452		
	5013743*PED	Aug 12, 2010				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
<u>ANASTROZOLE - ARIMIDEX</u>						
020541 001	RE36617	Dec 27, 2009	DS DP U-946			
<u>ARMODAFINIL - NUVIGIL</u>						
021875 002					NP	Jun 15, 2010
<u>ARMODAFINIL - NUVIGIL</u>						
021875 005					NP	Jun 15, 2010
<u>ARTEMETHER; LUMEFANTRINE - COARTEM</u>						
022268 001					>A> NCE	Apr 07, 2014
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 001	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 002	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 003	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 004	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZITHROMYCIN - AZASITE</u>						
050810 001	5192535	Mar 09, 2010	DP U-709			
	6239113	Mar 31, 2019	U-709			
	6569443	Mar 31, 2019	DP U-709			
	6861411	Nov 25, 2018	U-709			
	7056893	Mar 31, 2019	DP U-709			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
050819 001	5733886	Mar 31, 2015	DP U-124			
	6117843	Feb 18, 2012	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - DUAC</u>						
050741 001	5466446	Feb 16, 2014	DS DP			
<u>BENZYL ALCOHOL - BENZYL ALCOHOL</u>						
022129 001					>A> NCE	Apr 09, 2014
<u>BETAMETHASONE VALERATE - LUXIQ</u>						
020934 001	7078058	May 24, 2017	DP			
<u>BIMATOPROST - LATISSE</u>						
022369 001					NP	Dec 24, 2011
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
050786 001	5196205	Mar 23, 2010	U-933			
	5476669	Mar 23, 2010	U-933			
	6350468	Dec 14, 2018	U-956			
	6350468	Dec 14, 2018	U-932			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
020929 001	>A> 7524834	Nov 11, 2018	DP U-966			
	>A> 7524834*PED	May 11, 2019				
<u>BUDESONIDE - PULMICORT RESPULES</u>						
020929 002	>A> 7524834	Nov 11, 2018	DP U-966			
	>A> 7524834*PED	May 11, 2019				
<u>BUDESONIDE - PULMICORT RESPULES</u>						
020929 003	>A> 7524834	Nov 11, 2018	DP U-966			
	>A> 7524834*PED	May 11, 2019				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
021929 001					I-582	Feb 27, 2012
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
021929 002					I-582	Feb 27, 2012
<u>CALCITRIOL - VECTICAL</u>						
022087 001					NDF	Jan 23, 2012
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPICID COMPLETE</u>						
020958 001	5075114	May 23, 2010	DP			
	5075114*PED	Nov 23, 2010				
	6814978	Aug 26, 2021	DP			
	6814978*PED	Feb 26, 2022				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
021823 001	>A> 5583122	Dec 10, 2013	DS DP U-353			
	>A> 5583122*PED	Jun 10, 2014				
	>A> 5994329	Jul 17, 2018			U-353	
	>A> 5994329*PED	Jan 17, 2019				
	>A> 6015801	Jul 17, 2018			U-353	
	>A> 6015801*PED	Jan 17, 2019				
	>A> 6096342	Nov 21, 2011		DP		
	>A> 6096342*PED	May 21, 2012				
	>A> 6165513	Jun 10, 2018		DP		
	>A> 6165513*PED	Dec 10, 2018				
	>A> 6432932	Jul 17, 2018			U-595	
	>A> 6432932*PED	Jan 17, 2019				
	>A> 6465443	Aug 14, 2018		DP		
	>A> 6465443*PED	Feb 14, 2019				
<u>CICLESONIDE - ALVESCO</u>						
021658 002					NDF	Jan 10, 2011
					NCE	Oct 20, 2011
<u>CICLESONIDE - ALVESCO</u>						
021658 003					NDF	Jan 10, 2011
					NCE	Oct 20, 2011
<u>CLARITHROMYCIN - BIAXIN XL</u>						
050775 001	6551616	Jul 15, 2017			U-924	
<u>CLOBETASOL PROPIONATE - OLUX</u>						
021142 001	6126920	Mar 01, 2016			U-484	
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
020839 002	4847265	Nov 17, 2011	DS DP			
	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
021141 001	5607669	Jun 10, 2014			U-323	
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014			U-323	
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014				
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014			U-323	
	5917007*PED	Oct 29, 2014				
	5919832	Jun 10, 2014				
	5919832*PED	Dec 10, 2014				
	6066678	Jun 10, 2014			U-323	
	6066678*PED	Dec 10, 2014				
	6433026	Jun 10, 2014				
	6433026*PED	Dec 10, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
021176 001	5607669	Jun 10, 2014				
	5607669*PED	Dec 10, 2014			I-553 PED	Jan 18, 2011 Jul 18, 2011
	5679717	Apr 29, 2014				
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS		U-323	
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS		U-323	
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP		U-757	
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022			U-851	
	7229613*PED	Oct 17, 2022				
<u>CYCLOSPORINE - SANDIMMUNE</u>						
050625 001	>A> 7511014	Feb 16, 2010				DP
<u>CYCLOSPORINE - SANDIMMUNE</u>						
050625 002	>A> 7511014	Feb 16, 2010				DP
<u>CYCLOSPORINE - SANDIMMUNE</u>						
050625 003	>A> 7511014	Feb 16, 2010				DP
<u>DASATINIB - SPRYCEL</u>						
021986 001	>A> 7491725	Oct 13, 2025	DS DP			
<u>DASATINIB - SPRYCEL</u>						
021986 002	>A> 7491725	Oct 13, 2025	DS DP			
<u>DASATINIB - SPRYCEL</u>						
021986 003	>A> 7491725	Oct 13, 2025	DS DP			
<u>DASATINIB - SPRYCEL</u>						
021986 004	>A> 7491725	Oct 13, 2025	DS DP			
<u>DEGARELIX ACETATE - DEGARELIX ACETATE</u>						
022201 001	5925730	Apr 11, 2017	DS DP		U-943	
<u>DEGARELIX ACETATE - DEGARELIX ACETATE</u>						
022201 002	5925730	Apr 11, 2017	DS DP		U-943	
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
050818 001	5149694	Sep 22, 2009			U-953	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - KAPIDEX</u>						
022287 001	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
<u>DEXLANSOPRAZOLE - KAPIDEX</u>						
022287 002	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
020062 005	5286497	May 20, 2011	DP			
	5439689	Aug 08, 2012	DP U-107			
	5470584	May 20, 2011	DP			
<u>DINOPROSTONE - CERVIDIL</u>						
020411 001	>A> 5269321	Jul 14, 2012	DP U-110			
<u>DIVALPROEX SODIUM - DIVALPROEX SODIUM</u>						
077567 002					PC	Aug 01, 2009
<u>DOXERCALCIFEROL - HECTOROL</u>						
021027 001	5707980	Aug 17, 2010	U-321	Y		
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
022291 001	7473686	Jul 24, 2021	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
022291 002	7473686	Jul 24, 2021	DS DP U-930			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 001					NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 002					NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 003					NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021365 001					NPP	Mar 19, 2012
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021153 001					>A> NPP >A> PED	Apr 28, 2009 Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021153 002					>A> NPP >A> PED	Apr 28, 2009 Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021957 001					>A> NPP >A> PED	Apr 28, 2009 Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021957 002					>A> NPP >A> PED	Apr 28, 2009 Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
022101 001					>A> NPP >A> PED	Feb 27, 2011 Aug 27, 2011
<u>ESTRADIOL - ELESTRIN</u>						
021813 001	7470433	Aug 03, 2021	DP			
<u>EVEROLIMUS - AFINITOR</u>						
022334 001	5665772	Sep 09, 2014	DS DP		NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP			
	7297703	Dec 06, 2019	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
022334 002	5665772	Sep 09, 2014	DS DP		NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP			
	7297703	Dec 06, 2019	DP			
<u>FEBUXOSTAT - ULORIC</u>						
021856 001	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FEBUXOSTAT - ULORIC</u>						
021856 002	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FLUDARABINE PHOSPHATE - FLUDARABINE PHOSPHATE</u>						
022273 001	7148207	Dec 20, 2022	DP U-944		NDF	Dec 18, 2011
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 001	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 003	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 006	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 001	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 002	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 003	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 004	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 005	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 100</u>						
020833 002	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 250</u>						
020833 003	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 50</u>						
020833 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 001	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Jun 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 002	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 003	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015	U-710			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015	U-582			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015	U-583			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
021077 001	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
021077 002	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
021077 003	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
021254 001	5658549	Aug 19, 2014	DP			U-738
	5658549*PED	Feb 19, 2015				U-738
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP			U-738
	6253762*PED	Oct 14, 2015				U-738
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6341168	Jun 08, 2018	DP			
	6341168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017				
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021				U-841
	6743413*PED	Dec 01, 2021				U-841
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
021254 002	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6341168	Jun 08, 2018	DP			
	6341168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-841		
	6743413*PED	Dec 01, 2021		U-841		
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASON PROPRIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
021254 003	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6341168	Jun 08, 2018	DP			
	6341168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-841		
	6743413*PED	Dec 01, 2021		U-841		
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 001					M-83	Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 002					M-83	Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 003					M-83	Apr 14, 2011
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
022244 001	6204257	Jun 07, 2018	DS DP U-945		NCE	Dec 12, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADODIAMIDE - OMNISCAN</u>						
022066 002	5362475	Nov 08, 2011	DS			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
020622 001					I-594	Feb 27, 2012
<u>GLATIRAMER ACETATE - COPAXONE</u>						
020622 002					I-594	Feb 27, 2012
<u>GOSERELIN ACETATE - ZOLADEX</u>						
019726 001	7500964	Feb 26, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
020578 001	7500964	Feb 26, 2021	DP			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
021162 003	5591762	Jan 07, 2014	DS DP U-3			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021588 001					I-583	Dec 19, 2011
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021588 002					I-583	Dec 19, 2011
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
021536 001	5750497	May 16, 2019	DS DP U-668			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
021081 001	5656722	Aug 12, 2014	DS DP U-948			
	5656722*PED	Feb 12, 2015				
	7476652	Jul 23, 2023	DP			
	7476652*PED	Jan 23, 2024				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
021629 002					NCE	Apr 16, 2009
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
021629 003					NPP NCE	Oct 24, 2011 Apr 16, 2009
<u>IODIXANOL - VISIPAQUE 270</u>						
020351 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 270</u>						
020808 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
020351 002	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
020808 002	RE36418	Jul 12, 2011	DP			
<u>IXABEPILONE - IXEMPRA KIT</u>						
022065 001	6605599	May 26, 2018	DS DP U-961			
	6670384	Jan 23, 2022	DP U-960			
	6670384	Jan 23, 2022	DP U-959			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
>A>	7312237	Aug 21, 2024	U-965			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IXABEPILONE - IXEMPRA KIT</u>						
022065 002	6605599	May 26, 2018	DS DP U-961			
	6670384	Jan 23, 2022	DP U-960			
	6670384	Jan 23, 2022	DP U-959			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	>A> 7312237	Aug 21, 2024	U-965			
<u>LANSOPRAZOLE - PREVACID</u>						
020406 001					>A> M-85 >A> PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
020406 002					>A> M-85 >A> PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
021281 001					>A> M-85 >A> PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
021281 002					>A> M-85 >A> PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
021428 001	7431942	May 17, 2019	DP		>A> M-85 >A> PED	Oct 28, 2011 Apr 28, 2012
	7431942*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID</u>						
021428 002	7431942	May 17, 2019	DP		>A> M-85 >A> PED	Oct 28, 2011 Apr 28, 2012
	7431942*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID IV</u>						
021566 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	7396841	Aug 17, 2021	DP U-947			
	7396841*PED	Feb 17, 2022				
<u>LANSOPRAZOLE; NAPROXEN - PREVACID NAPRAPAC 500 (COPACKAGED)</u>						
021507 004	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 001	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 002	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 003	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 004	5968976	Oct 26, 2018	DP U-613			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPPRA XR</u>						
022285	002				NDF	Sep 12, 2011
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
022114	001				NPP	Jan 08, 2012
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021487	001	5061703	Apr 11, 2015	U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021487	002	5061703	Apr 11, 2015	U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021627	001	5061703	Apr 11, 2015	U-539		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256	001	6602911	Nov 05, 2021	U-882	NCE	Jan 14, 2014
	>A>	6992110	Nov 05, 2021	U-882		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256	002	6602911	Nov 05, 2021	U-882	NCE	Jan 14, 2014
	>A>	6992110	Nov 05, 2021	U-882		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256	003	6602911	Nov 05, 2021	U-882	NCE	Jan 14, 2014
	>A>	6992110	Nov 05, 2021	U-882		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256	004	6602911	Nov 05, 2021	U-882	NCE	Jan 14, 2014
	>A>	6992110	Nov 05, 2021	U-882		
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
021067	002	5394868	Jun 25, 2012	DP	NPP	Feb 01, 2011
		5394868*PED	Dec 25, 2012			
		5687710	Nov 18, 2014	DP		
		5687710*PED	May 18, 2015			
		5829434	Nov 03, 2015	DP		
		5829434*PED	May 03, 2016			
		5889015	Jan 27, 2014	U-645		
		5889015*PED	Jul 27, 2014			
		6057307	Jan 27, 2014	DP U-645		
		6057307*PED	Jul 27, 2014			
		6240918	Feb 20, 2017	DP		
		6240918*PED	Aug 20, 2017			
		6365581	Jan 27, 2014	U-645		
		6365581*PED	Jul 27, 2014			
		6503537	Mar 17, 2018	DP		
		6503537*PED	Sep 17, 2018			
		6677322	Jan 27, 2014	U-645		
		6677322*PED	Jul 27, 2014			
		6949532	Jan 27, 2014	U-645		
		6949532*PED	Jul 27, 2014			
<u>MORPHINE SULFATE - AVINZA</u>						
021260	005	6066339	Nov 25, 2017	DP		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - AVINZA</u>						
021260 006	6066339	Nov 25, 2017	DP			
<u>NITROGLYCERIN - NITROMIST</u>						
021780 001	5869082	Apr 16, 2016	DP			
<u>OLANZAPINE - ZYPREXA</u>						
020592 001	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 002	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 003	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 004	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 005	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 006	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 001	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 002	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 003	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 004	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OMEGA-3-ACID ETHYL ESTERS - LOVAZA</u>						
021654 001	5656667	Apr 10, 2017	DS DP U-822			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
022204 001	7029694	Apr 26, 2020	DP U-318		NDF	Jan 27, 2012
	7179483	Apr 26, 2020	U-318			
<u>PALIPERIDONE - INVEGA</u>						
021999 006	5158952	Oct 27, 2009	DP U-90			
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
020987 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
020987 002	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
022020 001	4758579	Jul 19, 2010	DS DP U-859			
	4758579*PED	Jan 19, 2011				
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
020988 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	6780881	Nov 17, 2021	DP			
	6780881*PED	May 17, 2022				
	7351723	Nov 17, 2021	DP			
	7351723*PED	May 17, 2022				
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
022159 001	>A> 6764678	May 11, 2021		U-967		
	>A> 6872390	May 11, 2021	DP			
	>A> 7229630	Jun 20, 2023	DP			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
021332 002	5814600	Sep 29, 2015		U-639		
	5814600	Sep 29, 2015		U-638		
	5814600	Sep 29, 2015		U-637		
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017		U-640		
	6114304	Sep 05, 2017		U-637		
	6608029	Sep 07, 2013		U-641		
	6608029	Sep 07, 2013		U-640		
	6608029	Sep 07, 2013		U-637		
	6610824	Mar 03, 2011	DS			
	7407934	Mar 08, 2011		U-640		
	7407934	Mar 08, 2011		U-637		
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
021332 003	5814600	Sep 29, 2015		U-639		
	5814600	Sep 29, 2015		U-638		
	5814600	Sep 29, 2015		U-637		
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017		U-640		
	6114304	Sep 05, 2017		U-637		
	6608029	Sep 07, 2013		U-641		
	6608029	Sep 07, 2013		U-640		
	6608029	Sep 07, 2013		U-637		
	6610824	Mar 03, 2011	DS			
	7407934	Mar 08, 2011		U-640		
	7407934	Mar 08, 2011		U-637		
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 001	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 002	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 003	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503 PED PED	Oct 20, 2009 Nov 13, 2011 Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 004	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503 PED PED	Oct 20, 2009 Nov 13, 2011 Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 005	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503 PED PED	Oct 20, 2009 Nov 13, 2011 Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 006	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503 PED PED	Oct 20, 2009 Nov 13, 2011 Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 007	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503 PED PED	Oct 20, 2009 Nov 13, 2011 Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 001	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575 I-574	Oct 08, 2011 Oct 08, 2011
	5948437	May 28, 2017	DP U-814		NDF	May 17, 2010
	5948437	May 28, 2017	DP U-601		PED	Apr 08, 2012
	5948437*PED	Nov 28, 2017			PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 002	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575 I-574	Oct 08, 2011 Oct 08, 2011
	5948437	May 28, 2017	DP U-814		NDF	May 17, 2010
	5948437	May 28, 2017	DP U-601		PED	Apr 08, 2012
	5948437*PED	Nov 28, 2017			PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 003	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575 I-574	Oct 08, 2011 Oct 08, 2011
	5948437	May 28, 2017	DP U-814		NDF	May 17, 2010
	5948437	May 28, 2017	DP U-601		PED	Apr 08, 2012
	5948437*PED	Nov 28, 2017			PED	Nov 17, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 004	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 005	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 001	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 002	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 003	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REPAGLINIDE - PRANDIN</u>						
020741 001	>A> 6677358	Jun 12, 2018	DS DP U-968			
<u>REPAGLINIDE - PRANDIN</u>						
020741 002	>A> 6677358	Jun 12, 2018	DS DP U-968			
<u>REPAGLINIDE - PRANDIN</u>						
020741 003	>A> 6677358	Jun 12, 2018	DS DP U-968			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 001	>A> 5583122	Dec 10, 2013	U-222			
	>A> 5583122*PED	Jun 10, 2014				
	>A> 6096342	Nov 22, 2011				
	>A> 6096342*PED	May 22, 2012				
	>A> 6165513	Jun 10, 2018				
	>A> 6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 002	>A> 5583122	Dec 10, 2013	U-222			
	>A> 5583122*PED	Jun 10, 2014				
	>A> 6096342	Nov 22, 2011				
	>A> 6096342*PED	May 22, 2012				
	>A> 6165513	Jun 10, 2018				
	>A> 6165513*PED	Dec 10, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 003	>A> 5583122	Dec 10, 2013	DS DP U-756		>A> I-309	Aug 11, 2009
	>A> 5583122	Dec 10, 2013	DS DP U-222		>A> PED	Feb 11, 2010
	>A> 5583122*PED	Jun 10, 2014				
	>A> 5994329	Jul 17, 2018		U-353		
	>A> 5994329*PED	Jan 17, 2019				
	>A> 6015801	Jul 17, 2018		U-353		
	>A> 6015801*PED	Jan 17, 2019				
	>A> 6096342	Nov 22, 2011		DP		
	>A> 6096342*PED	May 22, 2012				
	>A> 6165513	Jun 10, 2018		DP		
	>A> 6165513*PED	Dec 10, 2018				
	>A> 6432932	Jul 17, 2018		U-595		
	>A> 6432932*PED	Jan 17, 2019				
	>A> 6465443	Aug 14, 2018		DP		
	>A> 6465443*PED	Feb 14, 2019				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 004	>A> 5583122	Dec 10, 2013	DS DP U-353		>A> D-105	Apr 16, 2010
	>A> 5583122*PED	Jun 10, 2014			>A> PED	Oct 16, 2010
	>A> 6096342	Nov 22, 2011		DP U-353		
	>A> 6096342*PED	May 22, 2012				
	>A> 6165513	Jun 10, 2018		DP		
	>A> 6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 005	>A> 5583122	Dec 10, 2013	DS DP U-353		>A> NS	Apr 22, 2011
	>A> 5583122*PED	Jun 10, 2014			>A> PED	Oct 22, 2011
	>A> 6165513	Jun 10, 2018		DP		
	>A> 6165513*PED	Dec 10, 2018				
	>A> 7192938	May 06, 2023		U-353		
	>A> 7192938*PED	Nov 06, 2023				
<u>RISPERIDONE - RISPERIDONE</u>						
076440 001					PC	Jul 29, 2009
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
022008 006	>A> 5422123	Jun 06, 2012		DP	>A> NDF	Jun 13, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
020692 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>SILODOSIN - RAPAFLO</u>						
022206 001	5780485	Nov 13, 2012	U-902			
<u>SILODOSIN - RAPAFLO</u>						
022206 002	5780485	Nov 13, 2012	U-902			
<u>SINECATECHINS - VEREGEN</u>						
021902 001	5795911	Oct 31, 2020	U-172			
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 001					I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 004	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 005	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 006	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 007	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 004	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 005	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 006	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 007	5849700	Dec 15, 2015	U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015	DP U-340		I-551 I-536 ODE	Sep 20, 2010 May 31, 2010 May 31, 2014
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076572 001					>A> PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 001					>A> PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 002					>A> PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 003					>A> PC	Aug 08, 2009
<u>SUNITINIB MALATE - SUTENT</u>						
021938 004	6573293	Feb 15, 2021	DS DP U-703		NCE	Jan 26, 2011
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>TELBIVUDINE - TYZEKA</u>						
022154 001					>A> NCE	Oct 25, 2011
<u>TEMOZOLOMIDE - TEMODAR</u>						
022277 001	5260291	Aug 11, 2013	DS DP U-619			
	5260291*PED	Feb 11, 2014				
	6987108	Sep 08, 2023	DP			
<u>TIGECYCLINE - TYGACIL</u>						
021821 001					I-588 I-587 I-586	Mar 20, 2012 Mar 20, 2012 Mar 20, 2012
<u>TOPIRAMATE - TOPAMAX</u>						
020505 001	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 002	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 003	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 004	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 005	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 006	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX</u>						
020844 001	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020844 002	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
020844 003	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPIRAMATE</u>						
076448 001					>A> PC	Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
076448 002					>A> PC	Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
077868 001					>A> PC	Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
077868 002					>A> PC	Oct 12, 2009
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 001					NP	Dec 30, 2011
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 002					NP	Dec 30, 2011
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 003					NP	Dec 30, 2011
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
022278 001					NCE ODE	Dec 16, 2009 Dec 16, 2011
<u>ZOLEDRONIC ACID - RECLAST</u>						
021817 001					I-584 I-581	Mar 15, 2012 Dec 19, 2011
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
021997 001	6761910	Sep 24, 2018	DP U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
021997 002	6761910	Sep 24, 2018	DP U-674			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 29th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>